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ABSTRACT
ASPECTS OF MITOCHONDRIAL OXIDATIVE METABOLISM
by
Leslie Kushner
Adviser: Dr. Horst Schulz
The effects of metabolic intermediates and coenzymes on the activities of 
fa tty  acyl-CoA synthetase and carnitine palmitoyltransferase (CPT) in rat 
heart mitochondria were studied. ADP and palmitoyl-/-carnitine were weak 
inhibitors of fa tty  acyl-CoA synthetase. CPT A was inhibited 59.3% by 100 
/u.M succinyl-CoA. However, succinate thiokinase activity in ra t heart cytosol 
was too low to maintain a succinyl-CoA concentration sufficient to affect the 
activity of CPT A. There was no indication th a t fa tty  acid oxidation in rat 
heart mitochondria is controlled via the regulation of either CPT A or fatty  
acyl-CoA synthetase.
The dependence of the oxidation of unsaturated fa tty  acids containing cis 
double bonds on the presence of 3-hydroxyacyl-CoA epimerase was investi­
gated. The specific activity of epimerase in ra t heart mitochondria was found 
to be significantly lower than the rate of linoleoyl-CoA oxidation. Thus, it is 
the NADPH-dependent 2,4-dienoyl-CoA reductase, not the 3-hydroxyacyl-CoA 
epimerase, which functions in the oxidation of polyunsaturated fa tty  acids. 
[C.-H. Chu, L. Kushner, D. Cuebas, and H. Schulz, Biochem. Biophys. Res. 
Comm., vol. 118, pp. 162-167, 1984]
- iv -
3-Mercaptopropanoyl-CoA and S-acetyl-3-mercaptopropanoyl-CoA, phy­
siological metabolites of the known convulsant 3-mercaptopropanoic acid, were 
examined for their effects on purified pyruvate dehydrogenase complex from 
porcine and bovine heart. Both 3-mercaptopropanoyl-CoA and S-acetyl-3- 
mercaptopropanoyl-CoA were found to  be inhibitors of th is enzyme. Under 
optimal conditions, 50% inhibition was obtained a t 12.6 /tM 3- 
mercaptopropanoyl-CoA or 5.2 fxM S-acetyl-3-mercaptopropanoyl-CoA while 
100 fxM of the la tter compound gave 90% inhibition. The inhibition observed 
w ith S-acetyl-3-mercaptopropanoyl-CoA was demonstrated to be irreversible. 
Maximal inhibition of the complex and its component enzymes was observed 
when it was reacted w ith the inhibitor under conditions which promote reduc­
tion of the endogenous lipoate. [L. Kushner, D. Cuebas, and H. Schulz, Fed. 
Proc., vol. 43(7), pp. 1870, 1984]
Preliminary results indicate tha t S-acetyl-3-mercaptopropanoyl-CoA 
formed intramitochondrially inhibits pyruvate-supported respiration in ra t 
heart and liver mitochondria.
-  V -
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INTRODUCTION
Oxidation of fats and carbohydrates is a major mechanism by which cells 
obtain energy. In glycolysis, glucose is broken down to pyruvate in a series of 
reactions which occur in the cytosol. The pyruvate formed enters the mito­
chondria to be converted to acetyl-CoA by the pyruvate dehydrogenase com­
plex. Fatty acids are degraded to acetyl-CoA in mitochondria via the /3- 
oxidation pathway. The acetyl-CoA thus formed may either enter the TCA 
cycle to provide additional cellular energy or the citrate derived from the 
acetyl-CoA may leave the mitochondria and eventually supply acetate units 
which serve as building blocks for fa tty  acid synthesis. The relative activities 
of each of these pathways depends on the tissue being studied and the physio­
logical state of the organism. These tw o factors play a role in regulation of 
key enzymes of fa tty  acid and carbohydrate oxidation.
In mammalian liver, there is a reciprocal relationship between fa tty  acid 
and carbohydrate metabolism.1 In the carbohydrate-fed state, carbohydrates 
are oxidized and fa tty  acid synthesis occurs, while fa tty  acid oxidation is 
suppressed. In the carbohydrate-starved state, fa tty  acid synthesis is 
suppressed, while gluconeogenesis and fa tty  acid oxidation are the primary 
metabolic activities.2 A major point in regulation of these metabolic pathw ays 
is thought to be the carnitine acyltransferase (CPT)(EC 2.3.1.21) system which 
is located in the inner mitochondrial membrane.1
In mammalian heart, fa tty  acids are the main substrate for energy meta­
bolism,3 although glycolysis does occur. De novo fa tty  acid synthesis is not 
thought to be a major metabolic pathway in heart. However, some fa tty  acid 
elongation and complex lipid synthesis does occur in this tissue. Regulation of
- 2 -
these processes in heart tissue is not completely understood.
In tissues which oxidize fa tty  acids, the long-chain fa tty  acids in the cyto­
sol m ust be activated by the enzyme fa tty  acy 1-coenzyme A synthetase (EC 
6.2.1.3), which is located in the outer mitochondrial membrane4,5 , the endo­
plasmic reticulum6, 7 , and probably the peroxisome. The activated fa tty  acyl 
moiety can either be channeled into lipid biosynthesis or /3-oxidation.8 In order 
for 3-oxidation to occur, the fa tty  acyl moiety m ust cross the inner mitochon­
drial membrane. For long-chain fa tty  acyl groups, this process is facilitated 
by the carnitine acyltransferase system. It has been suggested th a t fa tty  acid 
activation and/or the carnitine acyltransferase reactions function as points of 
regulation in mammalian heart tissue.
Unsaturated fa tty  acids are also degraded by 3-oxidation in both liver and 
heart tissue. However, there is controversy over the enzymatic requirements 
for the shifting or removal of the double bonds and over the subcellular loca­
tion of the enzymes involved. The subcellular location of the enzymes is 
im portant since compartmentalization would have a bearing on the regulation 
of this metabolic process.
All tissues have the capacity for glycolysis. The final product of this 
pathway, pyruvate, is either reduced to lactate or oxidized in mitochondria. 
The pyruvate dehydrogenase complex is a key regulatory enzyme of the oxida­
tive metabolism of pyruvate in the mitochondria. There is a reciprocal rela­
tionship between the oxidation of carbohydrates and fa tty  acids.9 This recipro­
city is dependent on the synthetic needs of the cell, the energy demand of the 
cell, the availability of the different substrates, and the accumulation of
- 3 -
products. An increase in the intramitochondrial NADH/NAD+ ratio w ill inhi­
bit the TCA cycle10 , the 3-hydroxyacyl-CoA dehydrogenase (EC 1.1.1.35) 
reaction10 of /3-oxidation, and the pyruvate dehydrogenase complex.11’ 12, 13 An 
increase in the acetyl-CoA/CoASH ratio will inhibit both the 3-ketoacyl-CoA 
thiolase (EC 2.3.1.16) reaction14 of /3-oxidation and the pyruvate dehydro­
genase reaction.11’12’13 Factors which affect the key enzyme, pyruvate dehy­
drogenase complex, have an im portant bearing on the carbohydrate metabolism 
of all tissues. However, this is most critical in the brain, which has little, if 
any, capacity for /3-oxidation and derives most of its metabolic energy from 
glucose oxidation.15’ 16> 17
Regulation of F a tty  Acyl-CoA S ynthetase  and C arn itin e  P a lm ito y l­
tran sfe rase  o f M am m alian H eart M itochondria
Fatty  acids are the main substrates for energy metabolism in heart mus­
cle.3 Although the metabolic steps of /3-oxidation are well established, the regu­
lation of this pathway in heart muscle is not yet fu lly  understood.
Long-chain fa tty  acids in the cytosol m ust be activated by the enzyme 
fa tty  acyl-coenzyme A synthetase (EC 6.2.1.3), which is located in the outer 
mitochondrial membrane.4’5 This process may facilitate the translocation of 
activated fa tty  acids across the outer membrane.18 In heart tissue, the activated 
fa tty  acyl moiety can either be channeled into lipid biosynthesis or /3- 
oxidation.8 In order for /3-oxidation to occur, the fa tty  acyl moiety m ust cross 
the inner mitochondrial membrane. For long-chain fa tty  acyl groups, this pro­
cess is facilitated by the carnitine acyItransferase (CPT) (EC 2.3.1.21) sys­
tem .J9’ 20’21
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There are tw o CPT enzymes in the inner mitochondrial mem­
brane20, 22,23,24,25,26,27,28>29 : CPT A25,2^’27 or I28' 29 is loosely attached to 
the outer surface of the inner mitochondrial membrane; CPT B25,26,27 or 
II28,29 is located on the inner surface of the inner mitochondrial membrane (see 
Figure 1). Hoppel19 presents a convincing argument tha t the CPT I and II of 
Kopec and Fritz28, 29 are both CPT B.
Kopec and Fritz29 prepared antibodies to purified CPT I. One preparation, 
IG-I, inhibited the activity of only purified CPT I. Another preparation, IG-II, 
inhibited the activity of both purified CPT I and partially  purified CPT II. 
Brosnan et al. 20 showed th a t IG-II of Kopec and Fritz29 inhibited the CPT 
reaction on both the externai and internal surface of the inner mitochondrial 
membranes by 60% and 88%, respectively, while IG-I inhibited the CPT reac­
tion only on the external surface of the inner mitochondrial membrane, also by 
60%. They concluded that the two CPT reactions are not catalyzed by identi­
cal enzymes. If, as Hoppel19 believes, the CPT I and II of Kopec and Fritz28,29 
are both CPT B, then tw o further conclusions are possible: although both CPT 
enzymes are identical (or have some identical regions), the CPT A is more 
exposed to the external milieu than CPT B, thus exposing an additional 
antigenic determinant; or th a t the CPT B transverses the membrane and is 
exposed on both sides of the membrane. This last possibility is unlikely since 
trypsinization of the digitonin "mitoplast" left the CPT B activity intact.30
Although CPT A and CPT B have the same catalytic activity (both 
enzymes catalyze the forward and reverse reactions31 ), kinetic differences 
between the tw o enzymes have been demonstrated.27 The CPT from beef heart 
mitochondria was purified as a single protein.32,33,34 In addition, Bremer et
- 5 -
al.,35 present evidence tha t there are no distinct inner and outer CPT enzymes. 
When the inner and outer CPT were purified from  ra t liver mitochondria 
separately, they were shown to be kinetically and immunologically identical 
and have identical molecular weights.30 However, these same researchers 
demonstrated that there are differences between the inner and outer CPT in the 
intact mitochondrial membrane.30 It is likely tha t CPT A and CPT B are identi­
cal enzymes, altered in some w ay by their different locations in the mitochon­
drial membrane.
It has been suggested tha t fa tty  acid activation36, 37 or the carnitine acyl- 
transferase reactions may function as points of regulation for /3-oxidation in 
mammalian heart tissue.
In the perfused rat heart, at low levels of ventricular pressure, an increase 
in the concentration of palm itate in the perfusate causes a proportional increase 
in the rate of palmitate uptake. This is associated w ith a slight increase in tis­
sue levels of long-chain acyl-CoA, acyl-camitine, acetyl-CoA, and acetylcarni- 
tine. When the concentration of palm itate is increased above 0.6 mM, the rate 
of uptake does not increase further. In addition, the rate of oxygen consump­
tion and 14C 02 production from labelled palm itate remains constant. How­
ever, large amounts of acyl-CoA and acyl-camitine derivatives accumulate in 
the tissue. While the mass action ratio for CPT remains constant as the palmi­
tate concentration is increased, the mass action ratio of carnitine acetyl 
transferase shifts toward acetyl-CoA formation. Under these conditions, it 
appears tha t at palmitate concentrations in the perfusate between 0 and 0.6 
mM, /3-oxidation is limited by the rate of palm itate uptake or activation. At 
higher levels of palmitate, the rate of fa tty  acid uptake is limited by the
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availability of free CoASH and/or carnitine which are required for the fa tty  
acyl-CoA synthetase and the carnitine acyl transferase reactions, respectively. 
This finding is supported by the fact th a t acetyl-CoA oxidation through the 
TCA cycle is not accelerated under conditions of high exogenous palm itate con­
centration and also by the fact th a t the tissue ratios of acetyl-CoA/CoASH and 
acetylcam itine/cam itine continue to increase.38
Availability of carnitine may be a factor in limiting the rate of CPT A, 
while availability of CoASH may be a factor in limiting the rate of either the 
fa tty  acyl-CoA synthetase or CPT B. However, the effect of substrate availa­
bility on these enzymes may not be the limiting factor for /3-oxidation since the 
products of both reactions accumulate in the tissue. The subcellular locations 
of the metabolites measured and their concentration changes in each subcellular 
compartment (cytosol and mitochondria) under the conditions studied are more 
significant than whole tissue levels in determining the participation of CPT in 
limiting /3-oxidation and in determining whether the CPT enzymes could be 
controlled by changes in substrate availability.
Cytosolic and mitochondrial levels of CoASH and carnitine in rat heart 
and liver tissue have been estimated.37 Nearly all of the heart tissue CoASH 
was mitochondrially located, and 92% of this was free CoASH. In the liver, 
30% of the free CoASH was located in the cytosol. In both tissues it was 
determined th a t 100% of the free carnitine was in the cytosol. This is prob­
ably an overestimation due to  the loss of free carnitine during the preparation 
of mitochondria. The carnitine acylcamitine translocase facilitates the equili­
bration of free carnitine across the mitochondrial inner membrane.39 While this 
would function to maintain the same carnitine concentration in the cytosolic
- 7 -
and mitochondrial compartments of the cell, it would also allow carnitine loss 
f  rom mitochondria during the preparation of this organelle.
The maximal concentration of free CoASH in the cytosol was determined 
to be 22 /iM, but it would probably always be less due to the presence of some 
acyl-CoA.37 The Km for CoASH for the fa tty  acyl-CoA synthetase is 7 //.M but 
is 24 /j . M  in the presence of 8 /zM palmitoyl-CoA.37
These data do suggest, however, tha t the availability of free CoASH in the 
cytosol of heart tissue could be a limiting factor for fa tty  acid activation, and 
thus, /3-oxidation. There is evidence that the availability of free CoASH in the 
cytosol of brown adipose tissue is a limiting factor for fa tty  acid activation in 
tha t tissue.40
When acetyl-CoA oxidation in heart tissue is increased by increasing ven­
tricular pressure, the rate of palm itate uptake and /3-oxidation is also 
increased.38 This is associated w ith a decrease in tissue levels of fa tty  acids, 
acyl-CoA, acetyl-CoA, and acetyl-camitine, and w ith an increase in tissue lev­
els of acyl-camitine, free CoASH, and free carnitine.38 When palmitate is 
replaced by octanoate, which is able to cross the inner mitochondrial membrane 
bypassing both activation and the transfer to carnitine41 , oxidation is fast 
enough to maintain high tissue levels of acetyl-CoA. This occurs even when 
fa tty  acid oxidation is accelerated by increased ventricular pressure.38 It can be 
inferred that the rate of /3-oxidation may be limited by the availability of sub­
strate inside the mitochondria, which is dependent on the activation and 
transferase rates.
Palmitoyl-CoA is an inhibitor of fa tty  acyl-CoA synthetase, w ith a Ki of 
5 /zM. The inhibition can be relieved by addition of CoASH or albumin.37 
Since, in vivo, most of the cytosolic palmitoy 1-CoA is probably bound by pro­
tein, and since the carnitine level in the cytosol is quite high37 , thereby tending 
to drive any palmitoyl-CoA formed to palmitoy 1-carnitine, the inhibition of 
fa tty  acid activation by palmitoy 1-CoA is probably not physiologically 
significant. An exception would be in the ischemic heart, where the cytosolic 
concentration of acyl-CoA is estimated to rise as high as 17 /zM.37
The other products of the fa tty  acyl-CoA synthetase reaction, AMP and 
pyrophosphate, were found to be inhibitory at 1 mM. Acetyl-CoA, acetylcar- 
nitine, NAD+, NADH, glucose-6-phosphate, pyruvate, and TCA cycle inter­
mediates do not inhibit the reaction at 1 mM.37
Rat liver microsomal palm itate activation is inhibited by 5 mM AMP, 
ADP, and cyclic-AMP by 48%, 40%, and 40%, respectively.42 Rat liver mito­
chondrial palmitate activation is also inhibited by AMP and pyrophosphate.43
Total activity of the fa tty  acy 1-CoA synthetase in various tissues, includ­
ing heart mitochondria, has been shown to be greater than that required to sup­
port the highest rates of /3-oxidation and lipid biosynthesis.10-44 However, 
Normann et al.,36 found the fa tty  acyl-CoA synthetase of intact ra t heart 
mitochondria to have a four-fold lower activity than the CPT A. Regulation 
of fa tty  acid activation in vivo, may make this the rate-controlling step of /3- 
oxidation. The stimulation of palmitate oxidation in ra t skeletal muscle mito­
chondria caused by salicylic acid was due to the effect of this compound on the 
fa tty  acy 1-CoA synthetase.45 The fact that modification of the fa tty  acid
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activation step affects the entire /3-oxidation pathway implicates this as the rate 
limiting step. W hile it is likely th a t availability of cytosolic CoASH is a 
means of physiological regulation of this enzyme37 (for opposing view, see 
Pande, 197144 , 197246 ), other means of regulation have not been fully  inves­
tigated.
Examination of fa tty  acy 1-CoA synthetase has been done prim arily on tis­
sue other than heart, because it was thought th a t heart mitochondria did not 
possess this enzyme. Recently, it was demonstrated th a t lack of enzyme 
activity was due only to the method of preparation of ra t heart mitochon­
dria.4, 42 The protease, nagase was included in the preparation. This enzyme 
selectively inactivates fa tty  acyl-CoA synthetase w ithout an effect on the other 
enzymes of /3-oxidation.4
Possible inhibitors of fa tty  acy 1-CoA synthetase include ketone bodies, 
glycolytic intermediates, and ADP. These compounds were tested for their 
effect on fa tty  acyl-CoA synthetase in rat heart mitochondria isolated w ithout 
nagase.
Palmitoy 1-camitine is also a likely inhibitor of fa tty  acyl-CoA synthetase. 
In addition to  its structural sim ilarity to palmitate, the concentration of long 
chain acyl-camitines has been demonstrated to increase in heart tissue during 
reduced oxidative metabolism.38 In order to study the effect of palmitoy 1- 
camitine on fa tty  acyl-CoA synthetase, an attem pt was made to partially 
purify the enzyme, i.e. to separate fa tty  acy 1-CoA synthetase activity from car­
nitine palmitoyltransferase activity. This was undertaken because in ra t heart 
mitochondria the specific activity of both enzymes is the same. Since
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palmitoyl-CoA has been shown to inhibit the synthetase,37 CPT operating in 
the reverse direction may cause an apparent inhibition due to  accumulation of 
the CoA derivative - an inhibition which would be indistinguishable from that 
due to the added carnitine derivative.
It has been suggested th a t some factor in the cytosol stim ulates the 
activity of the fa tty  acyl-CoA synthetase.47*48 Aas and Dale2 have shown that 
refeeding of carbohydrate-starved rats causes a decrease in the fa tty  acid 
activation rate in liver and heart. Since the changes observed in liver are asso­
ciated w ith hormonal changes, the possibility exists th a t the effector of fa tty  
acyl-CoA synthetase is a kinase or phosphatase. Streptozotocin-induced dia­
betes caused a reduced rate of |3-oxidation and fa tty  acy 1-CoA synthetase 
activity in rat brown adipose tissue.49 In addition, adm inistration of O- 
tetradecanoylphorbol 13-acetate (TPA) decreased fa tty  acyl-CoA synthetase 
activity in ra t adipocytes.50 This compound is known to exert its effects on 
protein kinase C.51,52 Noradrenaline also caused a decrease in fa tty  acyl-CoA 
synthetase activity in adipose tissue.50 Cyclic AMP, an activator of certain pro­
tein kinases, stim ulated /3-oxidation in ra t hepatocytes.53 The possibility of 
activation or inactivation of rat heart fa tty  acyl-CoA synthetase by 
phosphorylation-dephosphorylation was investigated.
In mammalian liver, there is a relationship between fa tty  acid and car­
bohydrate metabolism.1 In the carbohydrate-fed state, carbohydrates are u til­
ized and fa tty  acid synthesis occurs, while fa tty  acid oxidation is suppressed. 
In this state the tissue level of malony 1-CoA is high. In the carbohydrate- 
starved state, fa tty  acid synthesis and malonyl-CoA production is suppressed, 
while fa tty  acid oxidation, gluconeogenesis, and ketogenesis are the primary
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metabolic activities. Under these conditions, CPT activity in liver is 
increased.2 In fact, it has been shown that the outer CPT activity increases to a 
much greater extent than total CPT activity.54 Simultaneously, hepatic carni­
tine levels and fa tty  acy 1-CoA levels increase. It has been demonstrated tha t 
high levels of carnitine55 and fa tty  acyl-CoA1 stim ulate /3-oxidation, while 
high levels of malony 1-CoA inhibit /3-oxidation.56 The site of malony 1-CoA 
inhibition has been identified as the CPT A.56,57,58>59 Recent evidence indicates 
th a t total CPT may be sensitive to malony 1-CoA inhibition.35' 60 In addition, 
sensitivity of CPT a ,54’61’62’63’64 ketogenesis65 and palmitate oxidation66’67 
to malonyl-CoA changes w ith the physiological state of the organism. 
W hether this is due to a change in the CPT A protein or a movement of CPT B 
to exposure on the outer surface54 is not known. Other evidence indicates that 
the changes in sensitivity of CPT to malony 1-CoA inhibition do not depend on 
a change in the CPT enzyme itself, but on some other " regulatory" component 
of the membrane35’60> 68 and may actually involve the synthesis of some new 
protein.69 The existence of a membrane regulatory component is supported by 
recent data which indicate th a t the malonyl-CoA binding site for ra t liver, 
heart, and skeletal muscle mitochondria is distinct from the active site of CPT 
A.70 In any case, such changes in kinetics indicate that this is a regulated 
enzyme.
Carbohydrate-starvation54’62> 64> 71> 72 and streptozotocin-induction of 
ketosis and diabetes61, 73 in rats have the same effect of diminishing the sensi­
tiv ity  of liver mitochondria CPT A to malony 1-CoA. Treatment of diabetic 
animals w ith insulin not only reverses ketosis, but increases the sensitivity of 
CPT A to malony 1-CoA.73 This indicates tha t this enzyme or regulation of this 
enzyme is under hormonal control.
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The evidence that CPT is a point of regulation for /3-oxidation in mam­
malian heart tissue is not as convincing.
Studies done to estimate cytosolic carnitine concentration37 reveal tha t this 
substrate is probably not limiting to the CPT A reaction in heart tissue.
Fong and Schulz74 demonstrated th a t the activities of CPT, 3-ketoacyl- 
CoA thiolase, and 3-hydroxyacyl-CoA dehydrogenase are nearly equal and 
lower than other enzymes of /3-oxidation in ra t heart mitochondria. They con­
cluded tha t inhibition of any of these enzymes could result in inhibition of 8- 
oxidation.
On the other hand, Pande44 showed that mitochondria from red and white 
skeletal muscle of rabbit and heart and liver of ra t respired as rapidly w ith 
palmitoy 1-CoA and carnitine as substrates as w ith palmitoy 1-carnitine This 
indicates tha t CPT A does not lim it /8-oxidation under normal conditions. In 
addition, CPT activity in rat heart and liver mitochondria and in skeletal mus­
cle mitochondria expressed in nmoles palmitoy 1-carnitine form ed/m in/m g pro­
tein was always greater than /3-oxidation expressed in nmoles palmitoy 1 group 
consumed/min/mg protein. However, the method used to assay for CPT 
activity did not distinguish between CPT A and CPT B, nor was the buffer used 
isoosmotic with the mitochondrial matrix. Therefore, values obtained for CPT 
activity probably reflect the sum of CPT A and CPT B activity.
It is still possible tha t accumulation of some metabolite in the cytosol has 
an inhibitory effect on CPT A, and thereby affects the rate of 3-oxidation by 
limiting the amount of substrate reaching the mitochondrial compartment.
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This seems to be the case for liver, where it has been shown th a t the rate 
of fa tty  acid synthesis can be hormonally modulated. Control of th is process 
using glucagon showed a positive correlation between the rate of fa tty  acid syn­
thesis and tissue malonyl-CoA concentration.75, 76 Both of these parameters 
correlated inversely w ith long-chain acyl-camitine concentration and the fa tty  
acid oxidation rate.76 In addition, it was shown that about 60% of the total 
CPT was sensitive to malonyl-CoA inhibition, while the remainder was totally  
resistant. The response of the sensitive CPT to  increasing malonyl-CoA con­
centration was paralleled by the effect on palm itate and palmitoy 1-CoA oxida­
tion, but showed no effect on the oxidation of palmitoy 1-carnitine.57
The CPT of heart mitochondria,77 brown adipose tissue mitochondria, 78 
muscle mitochondria,79 and brain mitochondria,80 is also inhibited by 
malony 1-CoA. In fact, CPT A from heart, muscle and adipose tissue was 
shown to be about 50 times more sensitive to malonyl-CoA than is the CPT A 
from liver. By adjusting the assay mixture w ith KC1 and sucrose to be 
isoosmotic w ith the mitochondrial matrix, Saggerson77 demonstrated that, in 
intact heart mitochondria, 93% of the overt CPT activity could be inhibited by 
malony 1-CoA. Thus, it is the CPT A that is malonyl-CoA sensitive.
Since fa tty  acid synthesis is a major metabolic pathway in liver and it has 
already been demonstrated that tissue levels of malonyl-CoA fluctuate, it is 
likely that malony 1-CoA accumulates in the cytosol of this tissue and inhibits 
CPT A. However, heart tissue does not actively synthesize fa tty  acids. Thus, 
it would be unlikely that malonyl-CoA appears in the cytosol of heart tissue in 
significant concentration. This has been disputed by McGarry et al.,81 who 
estimated total tissue contents of malonyl-CoA to be 2-8 nm ol/g w et w t in
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liver, heart and skeletal muscle of fed rats. In addition, the complex kinetic 
changes observed concerning CPT sensitivity to malonyl-CoA in ra t liver mito­
chondria are not seen in intact ra t heart mitochondria,35 nor are they seen in 
brain mitochondria.82
Aas and Dale2 observed changes in CPT activity in liver during fasting and 
refeeding, but not in heart. Therefore, it is unlikely th a t the CPT A of ra t 
heart mitochondria is regulated by the same mechanism as that of ra t liver 
mitochondria.
Possible inhibitors of CPT A include ketone bodies, glycolytic intermedi­
ates, ADP, ATP, NAD+, NADH. and carnitine derivatives. These compounds 
were tested for their effects on the CPT activity in ra t heart mitochondria. In 
additon, CoASH derivatives w ith structural similarities to malonyl-CoA have 
been tested for their effects on CPT A activity in intact ra t heart mitochondria. 
The mitochondria were kept intact by adjusting the osmolarity of the assay 
m ixture w ith KC1 and sucrose to be isoosmotic w ith the mitochondrial matrix. 
The intactness of the mitochondria is significant when examining the effect of 
CoASH derivatives on CPT A for several reasons: at the low level of inhibitor 
used, a significant amount can be lost due to the thioesterase activity present in 
the mitochondrial matrix 83 , thus masking the inhibition; and it has been 
demonstrated that malonyl-CoA only inhibits the membrane-associated 
enzyme and not the solubilized enzyme,57,59 although this has been disputed.35 
If other CoASH derivatives act similarly to malonyl-CoA, then the intactness 
of the mitochondrial membrane m ust be ensured in order to observe the inhibi­
tion.
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Oxidation of Unsaturated Fatty Acids in Mammalian Heart and Liver 
Mitochondria
Although the metabolic steps of /3-oxidation of saturated fa tty  acids is 
w ell known, the oxidation pathw ay of unsaturated fa tty  acids containing cis 
double bonds has not been fu lly  elucidated. The generally accepted pathway 
requires two enzymes, cis-A -trans-A  -enoy 1-CoA isomerase (EC 5.3.3.8) and 
3-hydroxy acy 1-CoA epimerase (EC 5.1.2.3), in addition to the normal /3- 
oxidation enzymes for the degradation of unsaturated fa tty  acids (see Figure 
2A).84 The isomerase catalyzes the conversion of 3-cz's-enoyl-CoA intermediates 
to the 2-trans isomer85 which can be further degraded by /3-oxidation. The 
epimerase catalyzes the epimerization of D-3-hydroxyacyl-CoA esters to the 
corresponding L-hydroxy isomers84 , which can be completely degraded by the 
normal /3-oxidation enzymes. Kunau and Dommes 86 have presented evidence 
tha t the oxidation of 4-cz's-decenoyl-CoA follows a different pathway requiring 
2,4-dienoyl-CoA reductase. Acyl-CoA dehydrogenase II catalyzes the conver­
sion of 4-a's-decenoy 1-CoA to 2-Trans,4-czs-decadienoy 1-CoA. This compound 
is reduced to 3-decenoyl-CoA by the NADPH-dependent 2,4-dienoyl-CoA
reductase86,87 ,(see Figure 2B). The 3-decenoyl-CoA thus formed is isomer-
3 2ized to 2-Trans-decenoy 1-CoA by the cz's-A -Trans-A -enoyl-CoA isomerase. 
This later compound can be further degraded by the normal enzymes of /3- 
oxidation. In addition, it was demonstrated that czs-4-decenoyl-CoA is 
degraded by beef liver mitochondria to octanoy 1-CoA w ithout the formation of 
cz's-2-octanoyl-CoA86 , an intermediate expected by the pathw ay of Stoffel and 
Caesar.84
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More recently, Cuebas and Schulz88 demonstrated tha t 2-trans,4-cis- 
decadienoyl-CoA, a metabolite of linoleate, cannot be degraded by the pathway 
proposed by Stoffel and Caesar.84 It was shown that while 2-transA-trans- 
decadienoyl-CoA is rapidly degraded via /3-oxidation, a mixture of 2-trans,4- 
czs-decadienoy 1-CoA and 2-cis,4-cis-decadienoyl-CoA can not be degraded via 
/3-oxidation by either ra t heart mitochondria or a reconstituted /3-oxidation 
system even when the crotonase concentration was increased 10 fold over the 
physiological level sufficient for the oxidation of 2-trans,4-trans-deeadienoyl- 
CoA.88 In addition, all three isomers of 2,4-decadienoyl-CoA were substrates 
for the NADPH-dependent 2,4-dienoyl-CoA reductase.88 The pathway pro­
posed by Cuebas and Schulz88 for the degradation of linoleic acid is presented 
in Figure 2B. The product of the reaction catalyzed by 2,4-dienoyl-CoA reduc­
tase is 3-decenoyl-CoA86’ 89 which can be isomerized to 2-trans-decenoy 1-CoA 
by the cis-A -trans-A  -enoyl-CoA isomerase.85 2-irans-Decenoyl-CoA can then 
be completely degraded by the normal /3-oxidation pathway.
Q O
Stoffel and Caesar84 have demonstrated tha t the cis-A -trans-A  -enoyl- 
CoA isomerase and the 3-hydroxyacyl-CoA epimerase are present in both rat 
liver and ra t heart mitochondria in addition to the normal 3-oxidation 
enzymes. In our laboratory, we have only been able to show an extremely low 
level of the epimerase activity in any mammalian heart tissue examined.90 It 
was not clear whether the epimerase activity observed in heart tissue could 
support the level of linoleic acid degradation expected by this tissue. In order 
to further investigate this point, oxidation of palmitoy 1-CoA, oleoy 1-CoA and 
linoleoyl-CoA were compared in ra t heart and rat liver mitochondria. These 
same mitochondrial preparations were examined for cis-A -ira/is-A -enoyl- 
CoA isomerase, 2,4-dienoyl-CoA reductase, and 3-hydroxyacyl-CoA epimerase
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activities by Mr. Chin-Hung Chu.91
Inhibition of Pyruvate Dehydrogenase Complex by Metabolites of 3- 
Mercaptopropanoic Acid
The convulsant, 3-mercaptopropanoic acid, is believed to cause seizures by 
interfering w ith the metabolism of the inhibitory neurotransmitter, y -  
aminobutyric acid (GABA), thereby causing a reduction in brain GABA concen­
tration.92 3-Mercaptopropanoic acid has been shown to  reversibly inhibit gluta­
mate decarboxylase 93> 94>95 and to activate GABA aminotransferase.95 It has 
also been suggested that 3-mercaptopropanoic acid disrupts energy metabolism 
in ra t brain mitochondria, possibly by affecting the utilization or formation of 
ATP.96 Sabbagh et al.,97 have shown 3-mercaptopropanoic acid to be a potent 
inhibitor of fa tty  acid oxidation in ra t heart mitochondria. Apparently, meta­
bolites of 3-mercaptopropanoic acid reversibly inhibit one or several of the |3- 
oxidation enzymes.98
It has been demonstrated that 3-mercaptopropanoic acid is activated in rat 
heart mitochondria. The 3-mercaptopropanoy 1-CoA thus formed is an 
effective substrate for thiolase (EC 2.3.1.9 and EC 2.3.1.16). When 3- 
mercaptopropanoyl-CoA substitutes for CoASH in the thiolytic cleavage of 
acetoacety 1-CoA, S-acetyl-3-mercaptopropanoy 1-CoA is formed (Figure 3).98
Since /3-oxidation is not a major pathway in brain15> 16>99 , the observed 
inhibition of this pathway in 3-mercaptopropanoic acid-treated rat heart mito­
chondria could not explain the onset of seizures in 3-mercaptopropanoic acid- 
treated rats. Oxidation of glucose is the major pathw ay of energy production
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in the brain15>17> 100 and inhibition of the key enzyme, pyruvate dehydro­
genase, in this pathw ay would have a profound effect on energy metabolism in 
this tissue. In addition, there is a close dependence of acetylcholine synthesis 
on the pyruvate dehydrogenase reaction.101,102,103 Since ketone bodies are oxi­
dized by brain tissue in proportion to their concentration in the blood16,104 , 
the presence of acetoacety 1-CoA in the brain exposed to 3-mercaptopropanoic 
acid may result in the production of S-acetyl-3-mercaptopropanoyl-CoA, 
intramitochondrially.
In view of this information, the effects of 3-mercaptopropanoy 1-CoA and 
S-acetyl-3-mercaptopropanoyl-CoA on pyruvate dehydrogenase complex and 
its component enzymes were investigated. In addition, the effects of S-aeetyl- 
3-mercaptopropanoic acid and 3-mercaptopropanoic acid on pyruvate-supported 
respiration in ra t heart and liver mitochondria were studied.
Aim of Research
Understanding the regulation of (8-oxidation in mammalian heart is the 
major research aim of this laboratory. Since fa tty  acid activation and the 
translocation of fa tty  acyl groups into the mitochondria via the carnitine acyl- 
transferase system are the first two committed steps of (3-oxidation, it is possi­
ble tha t this pathw ay is controlled by the regulation of either the fa tty  acyl- 
CoA synthetase or one of the CPT enzymes. Hence, I have studied the effects 
of metabolites and coenzymes on the activities of these tw o enzymes, especially 
the effects of malony 1-CoA and its structural analogs on the activity of CPT A. 
In addition, I have examined the possibility tha t the fa tty  acyl-CoA synthetase 
is regulated via phosphorylation-dephosphorylation. The results of these
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studies gave no indication th a t fa tty  acid oxidation in ra t heart mitochondria is 
controlled via the regulation of either CPT or fa tty  acyl-CoA synthetase.
Because of my experience in the isolation of mitochondria and measure­
ment of /3-oxidation, a new project was undertaken to demonstrate that the 
rate of oxidation of linoleoy 1-CoA in ra t heart mitochondria was too high to be 
dependent on the low level of epimerase found in tha t organelle.
When I completed the first part of my thesis research, other members of 
our laboratory had dem onstrated that 3-mercaptopropanoic iacid, a known con­
vulsive agent, is a potent inhibitor of fa tty  acid oxidation in rat heart mito- 
chndria.97 Since /3-oxidation is not a major pathway in brain15’ 16>99 , the 
observed inhibition of this pathway could not explain the onset of seizures in 
3-mercaptopropanoic acid-treated rats. When it was demonstrated, in our 
laboratory, tha t 3-mercaptopropanoic acid is activated and tha t the 3- 
mercaptopropanoy 1-CoA thus formed is an effective substrate for thiolase98 , 
the possibility tha t 3-mercaptopropanoy 1-CoA may act as a substrate or inhibi­
tor of pyruvate dehydrogenase occurred to me and this study was then under­
taken. In addition, inhibition of the pyruvate dehydrogenase reaction by S- 
acetyl-3-mercapopropanoy 1-CoA (the product of the thiolase reaction) was 
investigated. Pyruvate dehydrogenase was selected for this study because of 
its key role in the energy metabolism of brain.
- 2 0 -
EXPERIMENTAL PROCEDURES
Materials
Most organic chemicals and the pyruvate dehydrogenase complex were 
purchased from Sigma Chemical Co. NAD+, NADH, CoASH, and CoA deriva­
tives not synthesized in our laboratory were purchased from P-L Biochemicals. 
The enzyme, nagase, was purchased from the Enzyme Development Corp., New 
York, N.Y. Citrate synthase was purchased from Boehringer-Mannheim Corp. 
Radiolabelled compounds were purchased from New England Nuclear. Digito- 
nin was purchased from Calbiochem. Diketene and DCPIP were purchased 
from Aldrich Chemical Co. Oleic acid and linoleic acid were purchased from 
Supelco, Inc. L-Carnitine and palmitoy 1-L-carnitine were the generous gifts of 
Dr. K. Brendel, University of Arizona College of Medicine. S-Acetyl-3- 
mercaptopropanoic acid and bz's[2-carboxyethyl]disulfide were synthesized in 
our laboratory by Dean Cuebas. Pig heart 3-ketoacyl-CoA thiolase (EC 
2.3.1.16) was purihed by Mr. Chin-Hung Chu according to published pro­
cedures.105
Preparation of Rat Heart Mitochondria
Mitochondria were isolated from the hearts of adult male albino rats by 
the following method. The beating hearts were removed from tw o ether- 
anesthetized rats and placed in ice-cold MST buffer106 (210 mM mannitol, 70 
mM sucrose, 5 mM Tris, 1 mM EGTA, adjusted to pH 7.4 w ith HC1). The 
hearts were cut open, cleaned of blood vessels and washed free of blood in ice- 
cold MST buffer. The hearts were finely minced. The suspension was stirred
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continuously for 9 min a t 0°C w ith 6 mg of nagase, a general protease used to 
soften the heart tissue by degrading some of the connective tissue protein. 
This step was omitted if the mitochondria were to be used for the fa tty  acyl- 
CoA synthetase reaction. The resulting suspension was transferred to a glass 
homogenization tube. After dilution to approximately 30 ml in ice-cold MST 
buffer, the suspension was homogenized by 5 strokes of a loose-fitting Teflon 
pestle spinning at 750 rpm. If nagase was used, the homogenate was centri­
fuged at 20,000 rpm in an SS-34 rotor of a Sorvall Centrifuge for 7 min at 
5°C. The pellet was resuspended in about 30 ml of ice-cold MST buffer w ith a 
rubber policeman and homogenized by one stroke of the glass-Teflon tissue 
homogenizer. The resulting suspension was centrifuged twice at 10,000 rpm in 
an SS-34 rotor of a Sorvall Centrifuge for 7 min at 5°C. When nagase was not 
used, the homogenate was centrifuged at 10,000 rpm in an SS-34 rotor of a 
Sorvall Centrifuge for 7 min at 5°C. The pellet, each time, was resuspended in 
about 30 ml ice-cold MST buffer w ith a rubber policeman and homogenized by 
one stroke of the glass-Teflon tissue homogenizer. The resulting suspension 
was centrifuged at 2,300 rpm in an SS-34 rotor of a Sorvall Centrifuge for 5 
min at 5°C. The supernatant was decanted through tw o layers of cheesecloth 
into 15 ml Corex tubes. These tubes were centrifuged a t 8,000 rpm in an SS- 
34 rotor of a Sorvall Centrifuge for 7 min at 5°C. The mitochondrial pellets 
were resuspended into a small volume of ice-cold MST buffer using a rubber 
policeman. Mitochondria prepared in this way were used fresh or stored 
frozen at -80°C and used after thawing.
Integrity of the mitochondria isolated was assessed by determining the 
respiratory control ratio (RCR) and NADH dehydrogenase activity by means of 
oxygen consumption monitored at 25°C using a Clark oxygen electrode and
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Gilson Oxygraph. The standard incubation mixture contained in 2 ml, 0.11 M 
KC1, 33 mM Tris, 2 mM KPz, 2 mM MgCl2> 0.1 mM EGTA, pH adjusted to 7.4 
w ith HC1, and mitochondria (1 mg protein). For measuring the RCR, the incu­
bation mixture also contained 1 mg/ml BSA, 0.5 mM Z-malate, and 30 /iM 
palmitoy 1-Z-carnitine. The state III respiration was initiated by the addition of 
0.5 /imoles of ADP. State IV respiration was taken as the rate of oxygen con­
sumption after ADP depletion. The RCR is the ratio of state III to state IV 
respiration.
The NADH dehydrogenase reaction was initiated by the addition of 0.5 
/umoles of NADH to the standard incubation mixture. A conversion factor of 
1 nanoatom of oxygen consumed per nanomole of NADH oxidized was used.
Preparation of Rat Liver Mitochondria
Rat liver mitochondria were prepared from the livers of adult male albino 
rats by the following method. The liver of one ether-anesthetized ra t was 
removed and placed in ice-cold STE buffer (0.25 M sucrose, 5.0 mM Tris, 1 mM 
EGTA, adjusted to pH 7.4 w ith HC1). The liver was cleaned of large blood 
vessels and washed free of blood in ice-cold STE buffer. After finely mincing, 
2-3 g of the tissue was transferred to a glass homogenization tube and diluted 
to 35 ml in ice-cold STE buffer. This suspension was homogenized by 2 strokes 
of a loose-fitting Teflon pestle spinning a t 750 rpm. This was repeated until 
all of the tissue suspension was homogenized. The homogenate was centri­
fuged at 2,300 rpm in an SS-34 rotor of a Sorvall Centrifuge for 10 min at 
5°C. The supernatant was decanted through two layers of cheesecloth into 
fresh centrifuge tubes. These tubes were centrifuged at 10,000 rpm in an SS-
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34 rotor of a Sorvall Centrifuge for 10 min a t 5°C. The supernatants were 
discarded and the w hite fluffy layers were washed off the mitochondrial pellets. 
The pellets were resuspended into ice-cold STE buffer using a rubber policeman 
and transferred to 15 ml Corex tubes. These tubes were centrifuged at 9,000 
rpm in an SS-34 rotor of a Sorvall Centrifuge for 10 min at 5°C. The pellets 
were again washed and resuspended and finally centrifuged at 8,000 rpm for 10 
min. The final mitochondrial pellets were resuspended into a small volume of 
ice-cold STE buffer.
P rep ara tio n  o f Bovine H eart M itochondria32
Bovine heart mitochondria were prepared from fresh bovine heart stored 
several hours on ice. The entire procedure was performed a t 4°C. Ventricular 
tissue was cleaned of all fa t and connective tissue and cut into small pieces 
which were passed through a meat grinder. Portions of ground tissue (60 g) 
were blended at high speed in a Waring blender for 45s in 500 ml Buffer A 
(0.25 M sucrose, 5.0 mM HEPES, 0.25 mM EDTA, pH 7.7) followed by homo­
genization in 60 ml aliquots for 30s w ith a Polytron tissue homogenizer set at 
33% maximal speed. The homogenized samples were pooled and centrifuged 
for 15 min a t 500 x g, 15,000 x g, 500 x g, 11,000 x g, and 7,000 x g. High­
speed pellets were resuspended in isotonic buffer (0.25 M sucrose, 2.5 mM 
HEPES, 0.25 mM EDTA, pH 7.5) by two strokes of a glass-Teflon tissue homo- 
ginizer w ith a loose-fitting plunger set at 750 rpm. The 7,000 x g pellet was 
resuspended in a small volume of isotonic buffer using a rubber policeman and 
dispensed into test tubes which were stored a t -80°C.
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Preparation of Rat Heart Tissue Homogenate37
Homogenate was made from the hearts of adult male albino rats. The 
beating hearts were removed from ether-anesthetized rats and placed in ice-cold 
buffer (180 mM KC1, 10 mM Tris, 10 mM EDTA, 0.5 % (w /v ) BSA, pH 7.6). 
The atria and blood vessels were cleaned from the ventricular tissue, which was 
then washed free of blood in fresh buffer. The tissue was minced, then 
transferred to 6 ml ice-cold buffer in a 30 ml centrifuge tube and homogenized 
on ice w ith a Polytron tissue homogenizer w ith rheostat at 33% maximal speed 
for tw o 5-s periods. The homogenate was diluted in ice-cold buffer and homo­
genized in a glass-Teflon homogenizer w ith a loose-fitting pestle.
Subcellular Fractionation of Rat Heart Tissue
Method I
Hearts were obtained and minced as described on page 20. The finely 
minced hearts were transferred to a glass homogenization tube and diluted to 
approximately 30 ml in ice-cold MST buffer. The suspension was homogenized 
by 5 strokes of a loose-fitting Teflon pestle spinning a t 750 rpm. The homo­
genate was centrifuged at 2,300 rpm in an SS-34 rotor of a Sorvall Centrifuge 
for 5 min a t 5°C. A portion of the supernatant was retained as the whole 
heart homogenate. The remainder of the supernatant was centrifuged at
44,000 rpm in a Type-50 rotor of a Spinco Ultracentrifuge for 1 h r at 5°C. 
The high-speed supernatant was retained as the cytoplasmic fraction. The 
high-speed pellet was resuspended in a small volume of MST buffer and 
retained as the extracytoplasmal fraction. The three fractions were stored
- 25 -
overnight at -20°C. A fter thawing, the whole heart homogenate and the 
extracytoplasmic fraction were sonicated vising the microtip of a probe-type 
sonicator for 5 x 5 sec at 4°C. The sonicated fractions were centrifuged at
44,000 rpm in a Type-50 rotor of a Spinco Ultracentrifuge for 1 h r a t 5°C. 
The pellet was discarded.
Method I I
A homogenate of the rat heart tissue was obtained as in Method I. The 
homogenate was centrifuged at 10,000 rpm in an SS-34 rotor of a Sorvall Cen­
trifuge for 7 min at 5°C. The supernatant was retained as the cytoplasmic 
fraction. The pellet was resuspended in about 30 ml ice-cold MST buffer with 
a rubber policeman and homogenized by one stroke of a glass-Teflon tissue 
homogenizer. The resulting suspension was centrifuged at 2,300 rpm in an 
SS-34 rotor of a Sorvall Centrifuge for 5 min a t 5°C. The supernatant was 
decanted through two layers of cheesecloth into 15 ml Corex tubes. These 
tubes were centrifuged at 8,000 rpm in an SS-34 rotor of a Sorvall Centrifuge 
for 7 min at 5°C. The mitochondrial pellets were resuspended into a small 
volume of ice-cold MST buffer using a rubber policeman. The mitochondrial 
fraction was sonicated using the microtip of a probe-type sonicator for 5 x 5 
sec. Both the sonicated mitochondrial fraction and the cytoplasmic fraction 
were centrifuged at 44,000 rpm in a Type-50 rotor of a Spinco Ultracentrifuge 
for 1 hr an 5°C. The pellets were discarded.
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Measurement of Protein Concentration
Protein concentration was determined by either the Biuret Method107 or 
the Lowry M ethod108 using BSA as standard.
Measurement, of Oxygen Uptake by Mitochondria
Oxygen consumption w as monitored at 25°C by means of a Clark oxygen 
electrode and Gilson Oxygraph. The standard incubation m ixture for ra t heart 
mitochondria contained 0.11 M KC1, 33 mM Tris (pH 7.4), 2 mM KP;, 2 mM 
MgCl2> 0.1 mM EGTA, and mitochondria (O.r mg protein/m l). The standard 
incubation mixture for ra t liver mitochondria contained 0.1 M KC1, 20 mM 
Tris (pH 7.4), 4 mM KP; (pH 7.4), 4 mM MgCl2, 0.1 mM EGTA, and mito­
chondria (1 mg protein/m l). When palmitoyl-Z-carnitine (30 /xM) was used as 
substrate, 14.7 /xM BSA was included in the incubation mixture. When fatty  
acyl-CoA (15 /xM) was used as substrate, 14.7 /xM BSA, 0.5 mM L-malate, and 
13 mM /-carnitine was included in the incubation mixture. In addition, either 
0.5 mM malate or 5 mM a-ketoglutarate, was also included in the incubation 
mixture. After preincubation of the mixture for about 1 min, the reaction 
was started by the addition of ADP (final concentration, 1 mM) and substrate. 
Respiratory Control Ratios (RCR) were measured using 30 /txM palmitoy 1-/- 
cam itine as substrate, in the absence of carnitine.
Preparation of Malonyl-CoA
Reduced coenzyme A, Li salt (12.5 mg), S-malonyl-N-capryl cysteamine 
(17.4 mg), and sodium bicarbonate (42 mg) were placed in a test tube to which
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was added 1 ml of distilled water. This was left at room temperature for 1 
hr, then refluxed w ith ether for 30 min. The pH of the solution was adjusted 
to 1.0 w ith 2 N H2S 04. The solution was extracted w ith  ether for 30 min and 
adjusted to pH 5.0 w ith 1.0 N KOH. Residual ether was removed under a 
stream of nitrogen.
Preparation of Acetoacetyl-CoA 109
Reduced CoA, Li salt (8 mg), and 3 fxl of diketene were added to 1 ml of 
0.1 M potassium bicarbonate. This solution was stirred under a stream of 
nitrogen for 20 min a t room temperature. The pH was adjusted to 3-4 w ith 
concentrated HC1.
Preparation of Succinyl-CoA 110
Reduced CoA, Li salt (7 mg), was dissolved in 1 ml of ice-cold distilled 
water. Succinic anhydride (85.38 mg) was added and the pH adjusted to 8.0 
w ith 71.66 mg sodium bicarbonate. The mixture was kept in an ice bath for 
30 min with frequent shaking. The pH was brought to 2.0. The resulting 
solution was stored at -20°C.
For suceinyl-CoA solution devoid of CoASH the following procedure was 
performed at 0°C under nitrogen. Potassium bicarbonate (25 mg) was dis­
solved in 1 ml of ice-cold distilled water. The solution was evacuated w ith a 
stream of nitrogen prior to addition of 7 mg of reduced CoA, Li salt. Succinic 
anhydride (20 mg) was dissolved in 3 ml of dry THF and the resulting solu­
tion was added (6-8 drops at a time) to the CoASH solution until no yellow
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color was observed when a drop of the solution was added to  a drop of 
Ellm an’s reagent.111 The pH of the solution was brought to 1.0 and the THF 
removed by rotary evaporation under reduced pressure. The pH was brought 
to 2.0 and the resulting solution was stored a t -20°C.
Preparation of Oleoyl-CoA and Linoleoyl-CoA
Oleoyl-CoA and linoleoyl-CoA were prepared w ith  the assistance of Dean 
Cuebas by the mixed anhydride method of Goldman and Vagelos.112 During 
this procedure, all operations were carried out under nitrogen. The final aque­
ous solutions were stored under nitrogen in sealed ampules a t -76°C.
Preparation of 3-Mercaptopropanoyl-CoA
The mixed anhydride method of Goldman and Vagelos112 was used to 
synthesize the CoA derivatives of Ms-[2-carboxyethyl]-disulfide. The products 
formed were separated on a DEAE cellulose column by gradient elution w ith 0 
to 0.3 M LiCl, pH 4.0. The fractions containing 2-carboxyethyl- 
disulfidepropanoy 1-CoA were identified spectrophotometrically in a Gilford 
Spectrophotometer by measuring absorbance at 260 nm and 235 nm. The 
appropriate fractions were pooled and concentrated to 3.3 ml on an Amicon 
Diaflo Ultrafiltration membrane, YC 05, using 50 psi N2> The purity  of the 
product as determined by assessing the concentration of both adenosine and 
thioester. That of adenosine was measured spectrophotometrically at an 
absorbance of 260 nm; tha t of thioester was measured by the method of Ell- 
man.111 Theoretically, the ratio of adenosine to thioester bond should be 1:1.
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This solution was acidified to pH 1-2 w ith  HC1 and purged w ith nitrogen. 
The disulfide linkage was reduoed w ith 40-60 mg zinc dust w ith constant vor- 
texing under nitrogen until the Ellman Test 111 revealed th a t the reaction had 
gone to completion. The solution was filtered to remove excess zinc dust, and 
applied to a DEAE cellulose column. Gradient elution w ith 0 to 0.3 M LiCl, 
pH 4.0, th a t had been purged w ith N2 was performed. The fractions contain­
ing 3-mercaptopropanoy 1-CoA were identified spectrophotometrically by 
measuring the absorbance a t 260 nm. The appropriate fractions were pooled 
and concentrated to approximately 3.5 ml on an Amicon Diaflo Ultrafiltration 
membrane, YC 05, using 50 psi N2< The purity  of the product was determined 
by assessing the concentration of adenosine, free sulfhydryl group and thioes­
ter. That of adenosine was measured spectrophotometrically at 260 nm; that 
of free sulfhydryl group and thioester were measured by the method of Ell­
man.111 Theoretically, the ratio of adenosine to free sulfydryl group, to thioes­
ter bond should be 1:1:1. By this method, the solution was determined to con­
tain 88% 3-mercaptopropanoy 1-CoA and 12% dimerized 3-mercaptopropanoyl- 
CoA. The product was purged w ith nitrogen and stored a t -80°C. Prior to 
use, the solution was thawed and the concentration reassessed.
P repara tion  o f S-A cetyl-3-M ercaptopropanoyl-CoA
S-Acetyl-3-mercaptopropanoyl-CoA was synthesized by the mixed anhy­
dride method of Goldman and Vagelos.112 The crude product thus formed was 
purified on a DEAE cellulose column by gradient elution w ith 0 to 0.3 M LiCl, 
pH 4.0. The fractions containing S-acetyl-3-mercaptopropanoyl-CoA were 
identified spectrophotometrically by measuring absorbance at 260 nm and 235 
nm. The appropriate fractions were pooled and concentrated to 3.5 ml on an
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Amicon Diaflo Ultrafiltration membrane, YC 05, using 50 psi N2. The purity 
of the product was determined by tw o methods. Spectrophotometrically, the 
concentration of adenosine was determined by measuring the absorbance at 260 
nm, and the concentration of thioester was measured by the method of Ell- 
m an.111 Theoretically, the ratio of adenosine to thioester bond should be 1:2. 
The compound was always found to be greater than 99% pure by this method. 
HPLC was also used to  assess purity  of the product, using a W aters Microbon- 
dapak C l8 column and eluting w ith a gradient of 0.05 M ammonium phos­
phate buffer, pH 5.5, containing 15-30% methanol, in 3 min a t a rate of 1 
m l/m in. This method revealed three contaminants, w ith the major com­
ponent, S-acetyl-3-mercaptopropanoyl-CoA always representing at least 88% 
of the CoA-containing material.
Preparation of d,/-Dihydrolipoamide
Dihydrolipoamide was synthesized by the reduction of d,Z-lipoamide by 
the method of Reed et al..113 A suspension of 200 mg d,Z-lipoamide in 5 ml 
m ethanol/water, 4/1 (v /v ), was stirred at 0°C. A solution of 200 mg sodium 
borohydride in 1 ml w ater was cooled and added to the lipoamide suspension 
while stirring. The reaction m ixture was stirred until it became clear and 
colorless. The solution was acidified w ith HC1 and the methanol was eva­
porated under a stream of nitrogen. The aqueous solution remaining was 
extracted 5 times w ith 15 ml of chloroform. The resulting chloroform solu­
tion was evaporated to dryness under reduced pressure. The residue was 
recrystallized from a solution of petroleum ether and acetone to yield 46.91 mg 
of white plates; m.p. 63.5-65.5°C. A solution of 4.49 mM dihydrolipoamide 
yielded 8.44 mM free su lfhydryl group based on the Ellman’s
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determ ination.111
Ellman’s Determination111 of the Concentration of Coenzyme A Deriva­
tives
Hydroxylamine w ill cleave the thioester bond of a coenzyme A derivative. 
The resulting free CoASH w ill react w ith 5,5’-dithio-Ms-C2-nitrobenzoic acid) 
to  produce 5-thio-2-nitrobenzoate which absorbs light strongly at 412 nm w ith 
a molar extinction coefficient of 13,600 cm—1M—1 at pH 8.0.114
A small aliquot of the derivative (5-20 /il) was placed in a cuvette with 
20 ytil of 2 M hydroxylamine, pH 7.0. This was allowed to stand at room 
temperature for 5 min. To this was added 10 /u.1 of Ellman’s reagent, 300 /j . \  
of 0.1 M potassium phosphate buffer (pH 8.0), and distilled w ater to a total 
volume of 1 ml. Absorbance at 412 nm was read in a Gilson Spectrophotome­
ter. The value obtained was corrected for free CoASH in the solution by per­
forming the Ellman’s determination w ithout the addition of hydroxylamine.
Assay fo r  Palm itoyl-CoA  S ynthetase  A ctiv ity
Activity was measured based on the rate of production of [U-14Cl- 
palmitoy 1-CoA from [U-14C]-palmitate.6 The assay system contained 0.1 M 
Tris, 4 mM MgCl2, 5 mM reduced glutathione, 2 mM KCN, 5 mM malonate, 5 
mM ATP, 0.15 mM CoASH, 0.02 mM BSA, and 0.1 mM [U-14C]-palmitate 
(0.45 mCi/mmole) in a volume of 1 ml.
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The reaction was started by the addition of 0.25-0.30 mg of protein. The 
samples were incubated in a 37°C w ater bath and the reaction was stopped by 
the addition of 4 ml of Dole reagent 115 (isopropyl alcohol/n-heptane/1 N 
H2S 0 4, 40/10/1, v /v /v ) . Control tubes had Dole reagent added prior to  addi­
tion of protein. To each tube, 1.4 ml of distilled w ater and 2.4 ml of heptane 
were added. The sample was vortexed and centrifuged. The upper layer, con­
taining the unreacted palmitate, was removed. The lower aqueous layer was 
washed four times w ith 2.4 ml of heptane. An aliquot of the lower aqueous 
layer, containing [14C]-palmitoy 1-CoA, was placed in 10 ml of Bray’s solution 
and assayed for radioactivity by liquid scintillation counting in a Beckman 
Scintillation Counter.
Spectrophotom etric  Assay fo r  C arn itin e  P a lm ito y ltran sfera se  A c tiv ity 116
The assay was based on measuring the initial rates of RSH formation using 
the DTNB reaction. The product, 5-thio-2-nitrobenzoate, absorbs light 
strongly at 412 nm w ith  a molar extinction coefficient of 13,600 cm- 1 M—1 at 
pH 8.O.114
The assay system contained 116 mM Tris-Cl (pH 8.0), 0.09 % Triton X- 
100, 0.035 mM palmitoy 1-CoA, 0.11 mM DTNB, 1.1 mM Z-camitine, 1.1 mM 
EDTA* , in a volume of 1 ml.
The reaction was started by the addition of protein. Absorbance at 412 
nm was monitored over a time period of 2-5 min. The rate of free RSH
EDTA was demonstrated to be unnecessary for maximal activity and was omitted in several 
assays.
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formation by competing reactions was assayed by omission of carnitine from 
the assay mixture. This value was subtracted from th a t determined in the 
carnitine-containing mixture in order to determine the rate of CPT-generated 
CoASH formation.
Radiochemical Assay for Carnitine Palmitoyltransferase A ctivity77’ 78
Rat heart mitochondrial protein (0.05 mg) was preincubated a t room tem­
perature for 2 min in 1 ml containing 210 mM sucrose, 30 mM KC1, 50 mM 
Tris-HCl or MOPS-KOH, pH 7.4, 1 mM EGTA, BSA (1.3 mg/ml), 40 mmoles of 
Z-carnitine containing 0.6-1.0 ^Ci cZ,Z-[Me-14C]-carnitine or 1.1 /tzCi <2,Z-[Me- 
3H]-camitine and 40 /zM palmitoyl-CoA. The reaction was terminated after
2-4 min w ith 1 ml of ice-cold 1.2 M HC1 followed by 2 ml of water-saturated 
butanol. A fter vortexing and brief centrifugation, the butanol layer was 
washed w ith 5 ml of butanol-saturated water. An aliquot of the butanol 
layer was taken for liquid scintillation counting in 5 ml of Scintiverse II 
(Fisher Scientific) using a Beckman Liquid Scintillation Counter.
Hydrolysis of CoASH Derivatives Under Assay Conditions
The assay was based on measuring the rates of RSH formation using the 
5,5 ’-dithio-6A-(2-nitrobenzoic acid) reaction as described on page 31, under the 
conditions used in the radiochemical assay for carnitine palmitoyltransferase.
Rat heart mitochondria (0.05 mg) was added to 1 ml containing 210 mM 
sucrose, 30 mM KC1, 50 mM Tris-HCl or MOPS-KOH (pH 7.4), 1 mM EGTA, 
1.3 mg/ml BSA, 100 /zM CoASH derivative (palmitoyl-CoA was omitted).
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Absorbance at 412 nm was measured for 2 min. /-Carnitine (0.4 yumoles) was 
added and the absorbance at 412 nm was measured for at least 2 min. Initial 
rates of hydrolysis of CoASH derivatives were determined for the preincuba­
tion period (w ithout carnitine) and the reaction period (w ith carnitine).
Separation of Palmitoyl-CoA Synthetase Activity from CPT A ctivity
This procedure was based on the method described117 for the separation of 
the outer mitochondrial membrane from the " m itoplast".
A stock solution of 1.0% digitonin in isotonic beef heart mitochondria iso­
lation buffer was prepared by dissolving the digitonin in hot (almost boiling) 
buffer. After cooling to room temperature, BSA (50 m g/m l) was added to the 
solution. A volume of beef heart mitochondria (100 mg/m l protein) was 
placed in a pre-cooled vial on ice, to  which an equal volume of the digitonin 
stock solution was added. The mixture was stirred gently w ith a magnetic 
stirrer for 15 min on ice. The solution was diluted w ith 3 volumes of buffer 
and centrifuged at 9,000 x g in the SS-34 rotor of the Sorvall Centrifuge at 4°C 
for 10 min. The supernatant, which should contain the outer membrane vesi­
cles and intermembrane components117 , was retained. The pellet was brought 
to one half the original volume w ith buffer and centrifuged a t 9,000 x g in the 
SS-34 rotor of the Sorvall Centrifuge a t 4°C for 10 min. The resulting super­
natant was combined w ith the first supernatant, and the pellet was discarded.
The supernatant obtained was treated in one of tw o ways. Either the 
protein was precipitated out of solution by ammonium sulfate precipitation at 
4°C followed by centrifugation, or the protein was brought out of solution by
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ultracentrifugation at 144,000 x g for 1 h r in a Spinco ultracentrifuge. The 
pellets were resuspended in a small am ount of buffer and stored a t -80°C.
Assay fo r  Succinate T hiokinase (EC 6.2.1.4)118
Activity was measured based on the rate of production of succinyl-CoA 
from succinate and reduced CoASH. Tris-succinate, pH 7.4, was prepared as a 
solution containing 0.1 M succinate and 0.22 M Tris. The assay system, 1 ml 
in volume, contained 0.11 M Tris, 0.05 M succinate, 0.01 M MgCl2> 0.10 mM 
GTP, and 0.10 mM CoASH. The reaction was initiated by the addition of pro­
tein. The reactions were allowed to proceed at room temperature for 5, 20, and 
40 min, at which times a 250 fx 1 aliquot was removed to 25 fil of 1.2 N HC1 to 
stop the reaction. Controls were prepared by adding the appropriate amount 
of protein to a 250 fx\ assay system which had already been acidified. After 
10 min at pH 1, the solutions were brought to pH 3 w ith 10 fil of 1 M KOH.
When the assay was repeated on subcellular fractions obtained by Method 
II, it was performed in a volume of 250 fil containing, in addition to the usual 
components, 0.10 mM ATP. The reaction was stopped after 5 min by the 
addition of 40 /jlI of 1.2 N HC1. A fter 10 min a t pH 1, the solutions were 
brought to pH 3 w ith 15 /d  of 1 M KOH.
Succinyl-CoA content of each solution was determined by reversed-phase 
HPLC using a Waters Microbondapak C18 column w ith absorbance detection at 
254 nm. A gradient elution system was employed using 5-9% methanol in 0.5 
M ammonium phosphate buffer, pH 5.5, and a rate of 1.5 m l/m in. Peak area 
was measured.
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Assay for Citrate Synthase (EC 4.1.3.7)119
The assay was based on measuring the initial rates of RSH formation using 
the 5,5’-dithio-hi's-(2-nitrobenzoic acid) reaction of Ellman.111
The assay system, 1 ml in volume, contained 0.1M Tris-HCl (pH 8.1), 0.1 
mM DTNB, 0.3 mM acetyl-CoA, and 0.5 mM oxaloacetate. The enzyme source 
was added to the solution containing Tris, DTNB, and acetyl-CoA. The reac­
tion was initiated by addition of oxaloacetate. Absorbance at 412 nm was 
monitored over a time period of 2-5 min.
Assay for Enoyl-CoA Hydratase (EC 4.2.1.17)120
The assay mixture contained, in a volume of 1 ml, 0.35 M Tris-HCl (pH
7.4), and 85 /jlM crotonyl-CoA. The reaction was initiated by the addition of 
enzyme source. Absorbance change at 280 nm was measured in a Gilford Spec­
trophotometer.
Assay for 3-Hydroxyacyl-CoA Dehydrogenase (EC 1.1.1.35)116
Oxidation of NADH was measured spectrophotometrically a t 340 nm in a 
Gilford Spectrophotometer. The assay mixture contained, in a volume of 1 ml, 
0.35 M Tris-HCl (pH 7.0), 0.1 mM NADH, and 50 /ttM acetoacetyl-CoA. The 
reaction was initiated by addition of enzyme source.
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A ctivity of Pyruvate Dehydrogenase Complex
Pyruvate dehydrogenase complex was assayed spectrophotometrically at 
30°C as described by Pettit and Reed.121 The assay mixture contained, in a 
volume of 1 ml, 50 mM KP/ CpH 7.4), 1.0 mM MgCl2, 2.5 mM TPP, 65 yuM 
CoASH, 16 yuM dithiothreitol* , 2.0 mM sodium pyruvate (Sigma type II), 2.5 
mM NAD+, and the enzyme. Absorbance changes were monitored at 340 nm 
in a Gilford Spectophotometer.
A ctivity of Pyruvate Dehydrogenase (EC 1.2.4.1)
Pyruvate dehydrogenase was measured spectrophotometrically by the 
method of Lowe et al.122 , in an assay involving reduction of 2,6- 
dichlorophenolindophenol. The reaction mixture contained, in a volume of 1 
ml, 0.1 M KP; (pH 7.0), 100 yuM or 50 yuM dichlorophenolindophenol, 0.2 mM 
TPP, 1 mM MgCl2, 50 mM sodium pyruvate (Sigma type II), and the enzyme. 
The reduction of 2,6-dichlorophenolindophenol was measured spectropho­
tometrically at 600 nm in a Gilford Spectrophotometer.
This enzyme was also measured spectrophotometrically in an assay 
involving the reduction of ferricyanide. The reaction mixture contained, in a 
volume of 1 ml, 0.1 M KPi (pH 6.5), 18 or 1.8 mM potassium ferricyanide, 
0.14 mM TPP, 0.71 mM CaCl2, 36 mM sodium pyruvate (Sigma type II), 1.4 
m g/m l BSA, and the enzyme. The reduction of ferricyanide was measured 
spectrophotometrically at 410 nm in a Gilford Spectrophotometer.123
Dithiothreitol was demonstrated to be unnecessary for maximal activity and was therefore 
om itted in many of the assays.
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Activity of Pyruvate Dehydrogenase - Lipoate Acetyl Transferase
The combined pyruvate dehydrogenase - lipoate acetyl transferase activity 
was assayed by measuring the amount of acetyl-CoA produced. This was 
quantitated by converting it to citrate and CoASH.
pyruvate + lipoamide + CoASH ^  acetyl-CoA + dihydrolipoamide
acetyl-CoA + oxaloacetate -lua te  synth-~i> citrate + CoASH
The reaction mixture contained, in a volume of 2.5 ml, 50 mM Tris-HCl (pH
7.4), 1.0 mM MgCl2, 0.2 mM TPP, 65 /iM CoASH, 2.0 mM sodium pyruvate 
(Sigma type II), 0.4 mM lipoamide, and the enzyme. The reaction was stopped 
at various time intervals by addition of a 0.5 ml aliquot of the reaction mix­
ture to 0.5 ml of the citrate synthase reaction mixture containing 150 mM 
Tris-HCl (pH 8.1), 0.8 mM DTNB, and the citrate synthase. The reaction was 
initiated by the addition of 5.0 /m o les of oxaloacetate and allowed to go to 
completion. The absorbance at 412 nm, an absorbance maxima for 5-thio-2- 
nitrobenzoate which is released by the reaction of DTNB with free sulfhydryl 
groups114 , was measured spectrophotometrically in a Gilford Spectrophotome­
ter prior to the addition of oxaloacetate and after the reaction had gone to com­
pletion. The difference between the tw o values was used to determine the 
amount of acetyl-CoA produced.
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A ctivity of Lipoamide Dehydrogenase
Lipoamide dehydrogenase activity was assayed in both the forward and 
reverse direction by the method of Hayakawa et al..124 For the forward direc­
tion, the reaction mixture contained 50 mM KP/ (pH 6.5), 0.1 mM NAD+, 0.4 
mM dihydrolipoamide, 1.25 mM EDTA, and the enzyme, in a final volume of 1 
ml. For the reverse direction, the reaction m ixture contained 50 mM KP/ (pH
6.5), 0.1 mM NADH, 0.4 mM lipoamide, 1.25 mM EDTA, and the enzyme, in a 
final volume of 1 ml. The disappearance and formation of NADH were meas­
ured spectrophotometrically a t 340 nm in a Gilford Spectrophotometer.
Rapid Gel Filtration of Pyruvate Dehydrogenase Complex
Rapid gel filtration of the enzyme was performed by applying 0.1 ml of 
sample to a 1 ml Sephadex G-50 column which had been washed w ith 50 mM 
KP/ buffer (pH 7.4) containing BSA (10 m g/m l) and from which the void 
volume had been removed by centrifugation. The eluate was quickly collected 
by centrifugation of the charged column for 2 min in a clinical centrifuge. 
Samples were prepared, each containing in 0.2 ml, pyruvate dehydrogenase 
(0.085 mg protein), 50 mM KP/ (pH 7.56), 1 mM MgCl2, 0.2 mM TPP, 66.5 
/zm CoASH, 2 mM sodium pyruvate (Sigma Type II), ±235.25 yczM S-acetyl-3- 
mercaptopropanoyl-CoA, and incubated at room tem perature for 15 min. Just 
prior to centrifugation, BSA was added to the sample to give a final concentra­
tion of 0.3% BSA. Aliquots of 20 /zl were assayed immediately while 100 /zl 
of each sample was subjected to rapid gel filtration and then assayed for p y ru ­
vate dehydrogenase activity.
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NADH-Dependent Acetylation of the Pyruvate Dehydrogenase Complex
The NADH-dependent acetylation of the pyruvate dehydrogenase complex 
by [ l - 14C]-acetyl-CoA, was performed by the method of Collins and Reed.125
The reaction m ixture contained 0.2 -  0.22 mg pyruvate dehydrogenase 
complex, 50 mM KPi, pH 7.0, ImM MgCl2> 0.2 mM TPP, 0.1 mM NADH, and 
± S-acetyl-3-mercaptopropanoyl-CoA. This was preincubated at room tem­
perature for 3 min prior to initiation of the reaction w ith  10/d of 6.25 mM [1- 
14C]-acetyl-CoA, 10 /cCi/ml, to bring the volume of the reaction m ixture to a 
total of 250 /d . Aliquots of 50 /ul were removed from the reaction m ixture at 
5 min and 10 min and applied to squares (2x2 cm) of W hatm an No. 3MM 
filter paper. The papers were washed four times w ith  20 ml of ice-oold 10% 
trichloroacetic acid w ith shaking for 10 min each time. This was followed by 
washing twice w ith 20 ml of ice-cold ethanol w ith shaking for 5 min, followed 
by washing twice w ith 20 ml of ice-cold ether at room temperature w ith shak­
ing. The papers were placed in 5 ml of Scintiverse II (Fisher Scientific) and 
counted in a Beckman Scintillation Counter.
Effect of Enzymatically Prepared S-Acetyl-3-Mercaptopropanoyl-CoA on 
the Pyruvate Dehydrogenase Complex
S-Acetyl-3-mercaptopropanoyl-CoA was synthesized enzymatically using
3-mercaptopropanoyl-CoA as a substrate for 3-ketoacyl-CoA thiolase. Vary­
ing concentrations of 3-mercaptopropanoyl-CoA were added to a cuvette con­
taining 33 /cM acetoacetyl-CoA, 1.0 mM MgCl2, BSA (0.1 m g/m l), 0.1 M 
Tris-HCl, pH 8.0, and thiolase (33 m U /m l) in 1 ml. The reaction was
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observed to go close to completion by monitoring the change in absorbance at 
303 nm. The reaction was fu rther pulled to completion by conversion of the 
acetyl-CoA to citrate, catalyzed by citrate synthase.
The resulting solution containing S-acetyl-3-mercaptopropanoyl-CoA was 
made to contain 2.5 mM TPP, 130 /zM CoASH, 2.0 mM sodium pyruvate 
(Sigma Type II), and the pyruvate dehydrogenase enzyme. A fter 3 min incu­
bation at 30°C, the reaction was initiated by the addition of 10 /zl of 0.25 M 
NAD+ and the change in absorbance at 340 nm was measured using a Gilford 
Spectrophotometer.
The control reaction included CoASH instead of 3-mercaptopropanoyl- 
CoA in the thiolase reaction.
In assessing the effects of 3-mercaptopropanoyl-CoA and chemically syn­
thesized S-acetyl-3-mercaptopropanoyl-CoA on pyruvate dehydrogenase under 
these conditions, they were added to the assay mixture subsequent to the 
citrate synthase reaction.
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RESULTS AND DISCUSSION
Regulation of Fatty Acyl-CoA Synthetase and Carnitine Palmitoyl­
transferase
As indicated in Table 1, likely effectors of palmitoyl-CoA synthetase 
activity were tested at levels which are likely to be above their concentrations 
in heart cytosol. Ketone bodies, glycolytic intermediates, NAD+, and NADH 
had no effect on the enzyme. 5 mM ADP was found to inhibit synthetase 
activity by 41%. This was the same level of inhibition found for the rat liver 
microsomal enzyme.42 Octanoylcarnitine, at a concentration of 1 mM, was 
found to have no effect on the enzyme.
Palmitoylcarnitine was shown to have a significant effect on the activity of 
palmitoyl-CoA synthetase (Table 2). Palmitoylcarnitine at 1 mM inhibited 
the enzyme by 45%. As shown in Table 2 and Figure 4, raising levels of this 
carnitine derivative from 0 to 2 mM had an increasingly inhibitory effect on the 
enzyme. Inhibition of palmitoyl-CoA synthetase by palmitoylcarnitine never 
exceeded 45%.
Carnitine palmitoyltransferase activity in ra t heart mitochondria was 
determined to fall in the range of 11.4 to 15.0 nm ol/m in/m g protein, depend­
ing on the particular preparation. Since this activity was comparable to or in 
excess of the activity of the synthetase, it was considered tha t the CPT enzyme, 
acting in the reverse direction, could be masking the inhibitory effect by 
decreasing the effective concentration of palmitoy 1-carnitine in the assay mix­
ture. Alternatively, the same reaction could serve to increase the concentration
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of palmitoyl-CoA, which itself is an inhibitor of the synthetase.37
An attem pt was made to separate palmitoyl-CoA synthetase activity from 
carnitine palmitoyltransferase activity of beef heart mitochondria by digitonin 
fractionation. Digitonin selectively removes the outer membrane of liver mito­
chondria, w ithout an apparent effect on the inner mitochondrial membrane.117 
Because palmitoyl-CoA synthetase is located on the outer membrane4’5 and 
CPT on the inner membrane25’ 26,27,28,29 , it was expected tha t these activities 
could be separated by the digitonin fractionation procedure. It was further 
expected that the palmitoyl-CoA synthetase activity would be recovered in the 
"outer membrane plus intermembrane" fraction and that this fraction would be 
devoid of CPT activity. As shown in Table 3, the results were not as expected. 
Significant CPT activity was recovered in the "outer membrane" fraction. This 
is probably due to the fact that carnitine palmitoyltransferase A is loosely 
associated w ith the outer surface of the inner mitochondrial membrane and was 
easily removed by the perturbation. Other researchers have also had 
difficulties separating these tw o activities by membrane fractionation tech­
niques.126’ 127 In fact, Bergstrom and Reitz30 demonstrated tha t 25% of rat 
liver mitochondrial CPT was easily released and solubilized by digitonin treat­
ment. Hoppel and Tomec27 used this technique to  release CPT A from the 
membrane. In addition, this technique was developed for use w ith liver mito­
chondria and it is not known if it is effective w ith heart mitochondria.
The possibility of covalent modification of the palmitoyl-CoA synthetase 
by phosphorylation-dephosphorylation was investigated. Since such 
modification would be caused by a cytosolic protein such as protein kinase or 
protein phosphatase, assays were performed using whole heart tissue
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homogenate. Prior to assay for palmitoyl-CoA synthetase activity, the homo- 
genate was preincubated at 25°C w ith compounds known to regulate the activi­
ties of various protein kinases or phosphatases. Assays were performed w ith 
and w ithout the potential effectors included in the assay mixture.
2+A number of substrate proteins for Ca -dependent protein kinases have 
been identified in the cytosolic and mitochondrial fractions of guinea pig 
heart.128 These protein kinases were shown to be either phospholipid- or 
calmodulin-sensitive. Phosphorylation of one mitochondrial protein was aug­
mented by calmodulin in the presence or absence of added CaCl2>128 In addi­
tion, phosphorylation of a cytosolic and a mitochondrial protein catalyzed by a 
calmodulin-sensitive Ca2+-dependent protein kinase was inhibited by palmi­
toylcarnitine.128
ATP has been shown to stim ulate phosphorylation of acetyl-CoA carboxy­
lase via a protein kinase, in the absence of additional regulators.129- 130 Many 
protein kinases are cyclic-AMP-dependent131>132 , sometimes requiring preincu­
bation w ith cyclic-AMP prior to the addition of ATP.133 Fluoride, a known 
inhibitor of phosphatase,129 was also examined.
The results, shown in Table 4, indicate that regulators of protein kinases 
or protein phosphatases may cause either a slight stim ulation or a slight inhibi­
tion of palmitoyl-CoA synthetase. These effects, however, are too small to 
indicate regulation of the enzyme via phosphorylation-dephosphorylation.
As indicated in Table 5, likely effectors of CPT activity were tested at lev­
els equal to or greater than their maximal concentrations in heart cytosol.
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Pyruvate, lactate, NAD+, and NADH were shown to have an insignificant, if 
slightly stimulatory, effect on the enzyme. j3-Hydroxybutyrate, fructose-1,6- 
diphosphate, ADP, ATP, acetyl-camitine, and octanoyl-carnitine were shown to 
be slightly inhibitory. Pyruvate and lactate were also shown to have a 
slightly stim ulatory effect on CPT A (Table 6).
Mitochondria used in the assay for CPT A were kept intact by maintaining 
the osmolarity of the assay mixture as described. Respiratory control ratios, 
using palmitoylcarnitine as substrate, and NADH dehydrogenase activities were 
taken as indicators of intactness. Only mitochondrial preparations w ith a 
respiratory control ratio greater than 4.0 and NADH dehydrogenase activity 
less than 50 nm ol/m in/m g protein were used for the CPT A assays. In addi­
tion, there was very little  loss (less than 2%) of CoASH derivatives under the 
assay conditions (Table 7). This indicates th a t the CoASH derivatives were 
not exposed to thioesterase which is present in the mitochondrial m atrix.83
As expected, malonyl-CoA is a potent inhibitor of rat heart CPT A. 
Approximately 40% inhibition is obtained w ith 1 /zM malonyl-CoA under the 
conditions used (Table 8. Figure 5). Saggerson77 found 50% inhibition of rat 
heart CPT A with 1-2 /iM malonyl-CoA. Also consistent w ith the findings of 
Saggerson77 was the fact that Triton X-100 could abolish the inhibitory effects 
of malonyl-CoA on this enzyme (Table 6). This effect has also been demon­
strated w ith the liver enzyme.57
Since the presence of malonyl-CoA in the cytosol of heart tissue is not 
clearly established, its inhibitory effect on CPT A may not be physiologically 
significant. Other CoASH derivatives w ith structural similarities to malonyl-
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Co A were tested for their effect on this enzyme. Of those CoASH derivatives 
examined, only succinyl-CoA had an effect on the enzyme comparable to tha t 
of malonyl-CoA (Table 6). At 100 /xM, malonyl-CoA inhibited CPT A 
activity by 69.5%, while succinyl-CoA inhibited CPT A activity by 59.3% 
(Table 9). At 100 /xM, acetyl-CoA did not inhibit CPT A activity, while 
acetoacetyl-CoA and methylmalonyl-CoA inhibited the enzyme by 5.8% and 
23.0%, respectively. This agrees w ith the results of Mills et al.,134,135 who 
reported that, for rat liver, heart, and skeletal muscle mitochondrial CPT A, 
the inhibitory potency of CoASH derivatives followed the order malonyl-CoA 
>  succinyl-CoA >  methylmalonyl-CoA >  propanoyl-CoA >  acetyl-CoA. 
McGarry et al.,57 demonstrated that at 10 /xM CoASH, acetyl-CoA, 
propanoyl-CoA, and methylmalonyl-CoA did not inhibit rat liver CPT, while 
malonyl-CoA inhibited this enzyme by 40%. This indicates that it is impor­
tan t for the inhibitory compound to have a straight chain carbon skeleton w ith 
a carboxyl group on the terminal carbon in order for it to exert a significant 
effect on the enzyme.
Succinyl-CoA is not as potent an inhibitor of ra t heart CPT A as 
malonyl-CoA. While 1 /xM malonyl-CoA inhibits this enzyme by 40%, 
succinyl-CoA has no effect a t this concentration (Table 8, Figure 5). As shown 
in Table 8 and Figure 5, increasing the concentration of succinyl-CoA from 1 to 
100 /xM had an increasingly inhibitory effect of the enzyme. However, inhibi­
tion by suocinyl-CoA was always less than the inhibition by the same concen­
tration of malonyl-CoA.
Since the inhibition of ra t heart CPT A by succinyl-CoA was significant, it 
was considered tha t succinyl-CoA might be an inhibitor in vivo. In order for
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succinyl-CoA to be a physiological inhibitor of the CPT A, it m ust be present 
in the cytosol and its concentration m ust change in response to metabolic 
changes. Since, succinyl-CoA does not cross the mitochondrial membrane, any 
succinyl-CoA in the cytosol m ust be produced in that subcellular compartment. 
In order to determine whether succinyl-CoA can be formed in the cytosol, heart 
tissue was fractionated into cytosolic and extra-cytosolic fractions or cytosolic 
and mitochondrial fractions. Each subcellular. fraction was assayed for suc­
cinate thiokinase. Enoyl-CoA hydratase, 3-hydroxyacyl-CoA dehydrogenase, 
and citrate synthase activities were measured as mitochondrial matrix marker 
enzymes. As shown in Table 10 and 11, the cytosolic fraction does exhibit 
succinate thiokinase activity. However, the percent of total succinate thio­
kinase activity in the cytosol falls in the same range as that for the three mito­
chondrial m atrix marker enzymes present in the cytosol. Thus, the level of 
succinate thiokinase activity in the cytosolic fraction of ra t heart is not 
significantly different than the level expected due to leakage of mitochondrial 
m atrix enzymes. The leakage of mitochondrial enzymes is much higher for 
heart than for other tissues because harsher treatm ent is required for subcellu­
lar fractionation due to the toughness of the heart tissue. Based on these 
results it is unlikely that the cytosol of rat heart contains a high enough suc­
cinate thiokinase activity to maintain a level of succinyl-CoA inhibitory to the 
CPT A enzyme.
Since there was no effector of either the fa tty  acyl-CoA synthetase or the 
CPT enzymes which inhibited at a level deemed to be physiologically significant 
or was demonstrated to be in the cytosol, further kinetic studies of the 
observed inhibitions were not undertaken.
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Although much evidence exists for the regulation of /3-oxidation via the 
CPT enzyme or fa tty  acyl-CoA synthetase enzyme in tissues other than  heart, 
it  appears that these enzymes are not points of regulation for /3-oxidation in 
heart mitochondria.
Aas et al.,2 found that, under nutritional conditions (carbohydrate-starved 
or fat-fed) which increase CPT activity levels in ra t liver, neither CPT activity 
nor fa tty  acyl-CoA synthetase activity is affected in heart. They suggested 
that regulation of fa tty  acid metabolism in heart is regulated by availability of 
substrates.
Oxidation of Unsaturated Fatty Acids in Mammalian Heart and Liver 
Mitochondria
As shown in Table 12, the rates of oxidation of palmitoyl-CoA, oleoyl- 
CoA and linoleoyl-CoA in ra t liver mitochondria are approximately the same. 
Christopherson and Bremer136 , found the rates of oxidation of palm itoyl­
carnitine and oleoyl-carnitine in liver mitochondria to be the same, whereas 
that of linoleoyl-camitine was slightly lower and decreased w ith time. Reid 
and Husbands137 found tha t the oxidation rate of oleate and linoleate was 
higher than that of palm itate in ra t liver mitochondria. The rate of oxidation 
of linoleoyl-CoA in rat heart mitochondria is slightly less than th a t observed 
using palmitoyl-CoA or oleoyl-CoA as substrate. This agrees w ith the results 
of Christopherson and Bremer136 for oxidation of the corresponding carnitine 
derivatives. Lawson and Holman138 showed a slightly higher rate of oxidation 
of linoleoyl-CoA as compared to oleoyl-CoA in ra t heart mitochondria. Brown 
adipose tissue mitochondria also show similar oxidation rates w ith  palm itoyl-
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and linoleoyl-camitine.139
Assuming complete oxidation of the substrate in rat heart mitochondria, it 
was possible to calculate the nmoles of substrate consumed/min/mg protein 
(Table 13). Comparing these values to the specific activities of the three 
enzymes studied in this tissue (Table 14)91 , it is evident th a t the levels of
o 2
cis-A -trans-A -enoyl-CoA isomerase and 2,4-dienoyl-CoA reductase are in 
excess of th a t required for the oxidation of linoleoyl-CoA via the pathw ay pro­
posed by Cuebas and Schulz.88 3-Hydroxyacyl-CoA epimerase shows a greater 
specific activity w ith 3-D-hydroxydodecanoyl-CoA than w ith 3-D- 
hydroxyoctanoyl-CoA as substrate.91 If the specific activity for the epimerase 
in heart mitochondria using the C-12 substrate (3.42 nm ol/m in/m g protein) is 
compared to the specific activity for linoleoyl-CoA oxidation (3.06 nmol 
consumed/min/mg protein) in heart mitochondria, it would appear th a t this 
level of enzyme is sufficient to support oxidation of linoleoyl-CoA in heart 
mitochondria via the pathway proposed by Stoffel and Caesar.84 However, 
according to  this pathway, oxidation of linoleoyl-CoA would result in the for­
mation of 3-D-hydroxyoctanoyl-CoA as an intermediate and not the 3-D- 
hydroxydodecanoyl-CoA (Figure 2A). The specific activity of the epimerase in 
ra t heart mitochondria using 3-D-hydroxyoctanoyl-CoA as substrate (2.0 
nm ol/m in/m g protein)91 is significantly lower than w hat is required to explain 
the level of oxidation of linoleoyl-CoA in this tissue. Thus, it may be con­
cluded th a t at least a portion of the linoleoyl-CoA is oxidized by a pathway 
other than the one proposed by Stoffel and Caesar84 in ra t heart mitochondria 
and that the 3-hydroxyacyl-CoA epimerase is not necessary for the degradation 
of linoleoyl-CoA.
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Although 3-hydroxyacyl-CoA epimerase has been reported to exist in 
significant amounts in liver mitochondria84’91 >140 a rigorous study of the sub­
cellular location of this en2yme in ra t liver has shown it to be associated w ith 
peroxisomes, and not present in mitochondria.141 Therefore, the epimerase can­
not function in mitochondrial /3-oxidation of unsaturated fa tty  acids.
Inhibition of Pyruvate Dehydrogenase Complex by Derivatives of 3- 
Mercaptopropanoic Acid
Since 3-mercaptopropanoyl-CoA was able to substitute for CoASH in the 
thiolase reaction98 , it was thought tha t this compound might also be a sub­
strate for pyruvate dehydrogenase. When CoASH was excluded from the 
assay mixture and the reaction was initiated w ith 3-mercaptopropanoyl-CoA 
(to  65 £iM), the reaction rate and extent observed could be to tally  accounted 
for by some small amount of CoASH known to be present in the 3- 
mercaptopropanoyl-CoA solution. Thus, it was assumed that 3- 
mercaptopropanoyl-CoA could not substitute for CoASH in the pyruvate dehy­
drogenase reaction.
However, pyruvate dehydrogenase complex can utilize a-ketobutyrate  as 
substrate to produce propanoyl-CoA which is an end-product inhibitor of this 
enzyme.12 Thus, it was expected tha t 3-mercaptopropanoyl-CoA would inhibit 
the pyruvate dehydrogenase complex.
Inhibition of pyruvate dehydrogenase by 3-mercaptopropanoyl-CoA was 
demonstrated to be 50% at 12.6 /zM, and approached a maximum of 80% inhi­
bition at a concentration of 100 /zM (Figure 6A). The degree of inhibition
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caused by 3-mercaptopropanoyl-CoA was found to be a function of time, but 
was demonstrated to be about 50% complete a t approximately 1 min (Figure 
6B).
The normal product of pyruvate dehydrogenase is acetyl-CoA. I t is well 
known that acetyl-CoA exerts end-product inhibition on this enzyme.142 Since 
it has been demonstrated th a t 3-mercaptopropanoic acid is converted to S- 
acetyl-3-mercaptopropanoyl-CoA by mitochondrial enzymes,98 it was expected 
tha t the S-acetyl-3-mercaptopropanoyl-CoA thus formed would inhibit mito­
chondrial respiration by inhibiting the key enzyme, pyruvate dehydrogenase.
Under optimal conditions, 5.2 /iM  S-acetyl-3-mercaptopropanoyl-CoA 
inhibited the enzyme by 50%, while 100 yuM of this compound gave 90% inhi­
bition (Figure 6A). The degree of inhibition caused by S-acetyl-3- 
mercaptopropanoyl-CoA was found to be a function of time, yet was greater 
than 50% complete after only 5 seconds (Figure 6B).
The reversibility of the inhibition by S-acetyl-3-mercaptopropanoyl-CoA 
was investigated by subjecting the inhibited enzyme complex to rapid gel filtra­
tion on Sephadex G-50. If the inhibition is reversible, this process could 
restore enzyme activity through removal of the inhibitor.
As can be seen in Table 15, rapid gel filtration did not result in the reac­
tivation of the inhibited enzyme. Thus, the inhibition is irreversible. 
Although only approximately 50% of the enzyme activity was recovered during 
this process, the activity in the inhibited sample relative to the control was the 
same prior to and subsequent to filtration and therefore indicated no recovery
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of activity. In the absence of BSA all enzyme activity is lost, while increasing 
the BSA content of the applied sample and washing the column w ith BSA 
increased the activity recovered. Therefore, it is presumed tha t loss of enzyme 
activity during rapid gel filtration was due to a loss of protein on the column. 
Since activity was not restored to the inhibited enzyme by rapid gel filtration, 
the eluate was tested for the presence of S-acetyl-3-mercaptopropanoyl-CoA by 
HPLC. It was determined tha t only 8.4% of the applied S-acetyl-3- 
mercaptopropanoyl-CoA remained in the eluate. This meant tha t the assay 
m ixture for this sample contained 0.8 / j l M  S-acetyl-3-mercaptopropanoyl-CoA. 
This concentration of inhibitor could not account for the observed inhibition. 
In fact, if the inhibition were reversible, we would expect recovery of the 
enzyme activity to almost 100%.
Upon examination of S-acetyl-3-mercaptopropanoyl-CoA by HPLC tech­
niques, it was discovered tha t the solution contained three major contaminants: 
acetyl-CoA, 3.8 ± 1.8%; dimer CoA, 0.8 ± 0.4%; and an unidentified com­
ponent, 8.1 ± 1.1%. Thus, the S-acetyl-3-mercaptopropanoyl-CoA was 88.3 ±
0.1% pure. A ttem pts to purify the S-acetyl-3-mercaptopropanoyl-CoA by 
preparative HPLC resulted in a preparation which did not exhibit the inhibi­
tory  potency of the original solution, although none of the other peaks could 
account for the observed inhibition. In an effort to confirm that S-acetyl-3- 
mercaptopropanoyl-CoA was the inhibitor, it was synthesized enzymatically 
via the thiolase reaction. The inhibitory potency of enzymatically-synthesized 
S-acetyl-3-mercaptopropanoyl-CoA was compared to that of chemically- 
synthesized S-acetyl-3-mercaptopropanoyl-CoA and 3-mercaptopropanoyl- 
CoA. As can be seen in Table 16, inhibition of the pyruvate dehydrogenase 
complex is approximately the same for enzymatically and chemically
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synthesized S-acetyl-3-mercaptopropanoyl-CoA. A somewhat lesser degree of 
inhibition was observed here than was previously evidenced (Figure 6). It is 
likely this is due to the higher concentration of protein, especially BSA (which 
is known to bind certain CoA derivatives) and thiolase (which probably also 
binds 3-mercaptopropanoyl-CoA and S-acetyl-3-mercaptopropanoyl-CoA, the 
substrate and product, respectively, in the thiolase reaction).
Although citrate has been demonstrated to inhibit the pyruvate dehydro­
genase reaction,12’ 143 the maximum amount of citrate (60 /aM) which might be 
produced under these reaction conditions was demonstrated to have no effect on 
the activity of pyruvate dehydrogenase.
The extent of inhibition observed w ith both 3-mercaptopropanoyl-CoA 
and S-acetyl-3-mercaptopropanoyl-CoA was dependent on the preincubation 
conditions (Figure 7, 8, Table 17, 18). Maximal inhibition was observed when 
the enzyme was reacted w ith the inhibitor in the presenoe of either pyruvate 
and CoASH or NADH. These tw o conditions tend to promote reduction of the 
lipoate moiety of the enzyme. Somewhat less inhibition was observed when 
only CoASH, or CoASH and pyruvate in the absence of TPP were in the prein­
cubation mixture. Probably under these conditions CoASH alone could pro­
mote reduction of the lipoate moiety. The least inhibition occurred under 
those conditions which promote oxidation of the lipoate moiety of the enzyme,
i.e. when NAD+ was in the preincubation mixture. It is suggested th a t inhibi­
tion by 3-mercaptopropanoyl-CoA and S-acetyl-3-mercaptopropanoyl-CoA 
requires the lipoate moiety of the enzyme to be in the reduced state. Under 
other conditions, the presence of inhibitor caused the reaction rate to decrease 
w ith time. Addition of CoASH or pyruvate to the system after inhibition of
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the enzyme had no effect on reaction rate. Addition of fresh enzyme to the 
system restored the reaction rate to a rate somewhat less than the control 
values, indicating that the assay system was intact and tha t there was no accu­
m ulation of inhibitory product in the mixture. A t some point in the pyruvate 
dehydrogenase reaction, the reduced lipoate is made available. This may 
account for the observed increase in inhibition during the course of the reaction.
In general, it was found tha t inhibition of pyruvate dehydrogenase com­
plex, in the absence of substrates in the preincubation m ixture varied substan­
tially from enzyme preparation to preparation. Since the degree of oxidation or 
reduction of lipoate moieties is not altered by the preincubation conditions in 
this case , it is assumed that the degree of observed inhibition reflects the degree 
of reduction of the lipoate moieties of the enzyme preparation.
One notable difference between inhibition by the tw o compounds bears 
mentioning. The enzyme was, to a small degree, protected from inhibition by 
S-acetyl-3-mercaptopropanoyl-CoA when pyruvate was included in the prein­
cubation mixture. Under this condition, the lipoate would be acetylated and 
might not be as accessible to modification as in the reduced state. Under the 
same conditions, however, inhibition by 3-mercaptopropanoyl-CoA was 
enhanced somewhat. Apparently the acetylation of the lipoate moiety 
enhances inhibition by 3-mercaptopropanoyl-CoA. One possible explanation is 
that the 3-mercaptopropanoyl-CoA might participate, to some small degree, in 
the lipoate acetyltransferase (E2) reaction to produce S-acetyl-3- 
mercaptopropanoyl-CoA and reduced lipoate. 3-Mercaptopropanoyl-CoA 
would thus inhibit the enzyme via this additional mechanism.
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The pyruvate dehydrogenase complex contains three enzymes; pyruvate 
dehydrogenase (EC 1.2.4.1), lipoate acetyl transferase (EC 2.3.1.12), and dihy- 
drolipoyl dehydrogenase (EC 1.6.4.3). The reactions catalyzed by the enzymes 
in the complex are illustrated in Figure 9. The reaction catalyzed by the com­
plex has an absolute requirement for pyruvate, CoASH, and NAD+. Thus, the 
overall reaction can be initiated by the addition of one or more of any of these 
substrates. The order of addition of these substrates may have an effect on the 
state of the enzyme, particularly on the lipoate portion of the lipoate acetyl 
transferase. In addition, it can be seen tha t the process of the reactions brings 
the lipoate moiety through three states; the acetyl-bound state, the oxidize4 
state, and the reduced state.
Inhibition of the component enzymes of the pyruvate dehydrogenase com­
plex by S-acetyl-3-mercaptopropanoyl-CoA was also maximal under preincu­
bation conditions, which tend to promote reduction of the lipoate moiety.
Assessing the effect of S-acetyl-3-mercaptopropanoyl-CoA on pyruvate 
dehydrogenase, the first component enzyme of the complex, proved impossible. 
Due to the slow rate of the reaction, it was not possible to assay the enzyme by 
the method involving reduction of DCPIP. This method has been shown to 
cause the progressive inhibition of the pig heart pyruvate dehydrogenase com­
ponent by modification of enzyme-bound TPP.144 The method employed was 
based on the reduction of ferricyanide and yielded a specific activity of 0.21 
/xmol/hr/mg protein. This value is comparable to tha t of 5.7 /umol/hr/mg 
protein reported by Hayakawa et a l . ,124 who used slightly different conditions, 
which may have enhanced the activity of the enzyme. In any case, the enzyme 
activity was too low for inhibition to be effectively examined.
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The second component enzyme of the complex, lipoate acetyl transferase, 
is usually assayed by the determination of heat-stable thioester formed in the 
reaction of constantly generated acetyl-CoA w ith dihydrolipoamide in the 
absence of CoASH. This assay could not be employed because the inhibitor 
molecule, S-acetyl-3-mercaptopropanoyl-CoA, is a heat-stable thioester. In 
addition, the inhibitor molecule is thought to act by forming a heat-stable 
thioester w ith dihydrolipoate or dihydrolipoamide.
The first and second component enzymes of the pyruvate dehydrogenase 
complex were assayed together by measuring, via the citrate synthase reaction, 
the amount of acetyl-CoA produced. As shown in Table 19, when lipoamide 
was absent from the preincubation mixture, but pyruvate was present, the 
inhibition was significantly greater than under other conditions. This condi­
tion tended to promote the reduction of the endogenous lipoamide during the 
preincubation period, thus making it available for reaction w ith the inhibitor. 
It should be noted that exogenous lipoamide cannot participate in these reac­
tions directly.113 It can, however, drive the reaction by oxidizing enzyme- 
bound dihydrolipoate in the absence of NAD+ by the following reaction 
sequence:
I
S S HS SH HS S S SH HS SH S S
Thus, endogenous lipoate will be regenerated for reaction w ith  pyruvate. The 
fact that inhibition was nearly the same in the presence or absence of lipoam­
ide, when pyruvate was omitted during preincubation, suggests th a t most of
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the endogenous, enzyme-bound lipoate was in the oxidized state. Including 
pyruvate in the preincubation, but omitting lipoamide, would tend to generate 
endogenous enzyme-bound dihydrolipoate in the process of the reaction. Inhi­
bition was enhanced under these conditions, suggesting that reduced endogenous 
lipoate is necessary for the inhibitor to exert its effect.
The third component enzyme of the pyruvate dehydrogenase complex, 
dihydrolipoyl dehydrogenase, was assayed in both the forward and reverse 
direction by measuring the appearance or disappearance of NADH. Exogenous 
dihydrolipoamide or lipoamide can be, and was, used as substrate for the for­
w ard or reverse reaction, respectively. Because, under conditions where the 
inhibition of the pyruvate dehydrogenase complex was minimal, inhibition 
increased w ith time (Figure 8), it was thought that some process of the reaction 
(possibly making reduced lipoate available) contributed to the inhibition. By 
assaying the dehydrogenase enzyme w ith exogenous lipoamide, the step thought 
to be critical to inhibition (enzymatically catalyzed binding of S-acetyl-3- 
mercaptopropanoyl-CoA to reduced endogenous lipoate) was bypassed. Thus, 
it was expected that S-acetyl-3-mercaptopropanoyl-CoA would have no effect 
on this enzyme.
Contrary to expectation, Table 20 shows that dihydrolipoyl dehydro­
genase was inhibited in both directions under certain conditions. In the for­
w ard direction, the enzyme was inhibited only when dihydrolipoamide was in 
the preincubation mixture together w ith the inhibitor and when NAD+ was 
used to initiate the reaction. In the reverse direction, inhibition only occurred 
when NADH was included in the preincubation mixture with the inhibitor and 
lipoamide was used to initiate the reaction. These data are not inconsistent
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w ith the hypothesis tha t S-acetyl-3-mercaptopropanoyl-CoA reacts irreversibly 
w ith  endogenous dihydrolipoate. However, the fact tha t inhibition of the 
dehydrogenase portion of the enzyme still occurs in the presence of exogenous 
lipoamide indicates that the inactivation of endogenous lipoate cannot totally 
explain the observed inhibition of the pyruvate dehydrogenase complex. One 
possible explanation is apparent from the fact tha t inhibition of the dehydro­
genase was only seen under those conditions which tended to promote reduction 
of endogenous lipoate. In fact, under conditions which promoted oxidation of 
endogenous lipoate, no significant inhibition was observed. The hypothesis 
could be expanded to include the possibility tha t covalently modified 
endogenous lipoate may compete for the lipoamide site on the dehydrogenase. 
This modified endogenous dihydro1 ipoate would be a very effective competitive 
inhibitor compared to covalently modified exogenous lipoamide, because of its 
close proxim ity to the active site of the enzyme.
However, it cannot be ruled out that the S-acetyl-3-mercaptopropanoyl- 
CoA directly inhibits the dihydrolipoyl dehydrogenase reaction. Several inhi­
bitors of this enzyme are known.145’ 146 In the E. coli pyruvate dehydrogenase 
complex, p-[(bromoacetyl)-amino]phenyl arsenoxide binds first to the reduoed 
lipoyl residues (via its arsenoxide moiety) on the lipoate acetyltransferase. 
This is followed by an irreversible alkylation of histidine and cysteine in the 
active site of the dihydrolipoyl dehydrogenase, resulting in inhibition of this 
reaction and the overall reaction of the pyruvate dehydrogenase complex.145 Pig 
heart dihydrolipoyl dehydrogenase is inhibited by l,3-bzs~(2-chloroethyl)-l- 
nitrosourea.146 This inhibition is dependent on the reduction of a cystine 
disulfide located w ithin the active site of the enzyme. The inhibition can be 
prevented by preincubation of the enzyme with lipoamide. Thus, inhibition of
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dihydrolipoyl dehydrogenase by S-acetyl-3-mercaptopropanoyl-CoA may fol­
low a similar pattern in tha t this component enzyme is inhibited tinder reduc­
ing conditions, and the inhibition is prevented by preincubation of the enzyme 
w ith lipoamide. This, however, would have to be in addition to the inhibition 
of the E1E2 portion of the pyruvate dehydrogenase complex which was demon­
strated (Table 19).
The site of inhibition by S-acetyl-3-mercaptopropanoyl-CoA was further 
investigated by examining its effect on the incorporation of radioactively 
labelled acetyl groups from acetyl-CoA into the pyruvate dehydrogenase com­
plex. In the presence of NADH, the lipoate moiety of the lipoate acetyl- 
transferase (E2) is reduoed via the lipoamide dehydrogenase (E3) reaction. In 
the reverse reaction, the reduced lipoate can be acetylated from the product, 
acetyl-CoA. Since mammalian pyruvate dehydrogenase complex contains a 
dihydrolipoyl transacetylase core consisting of 60 polypeptide chains each con­
taining one molecule of covalently bound lipoic acid,147 the upper lim it for ace­
ty l groups bound per pyruvate dehydrogenase complex is 60. If the acetyl- 
CoA binding site is blocked by the inhibitor or the inhibitor itself reacts w ith 
the reduced lipoate, the acetylation of the pyruvate dehydrogenase complex 
w ill be inhibited. It must be pointed out tha t there is another binding site for 
acetyl-CoA, demonstrated for the E. coli enzyme148' 149>150> 151 which is on the 
pyruvate dehydrogenase (E l) and is a site for allosteric inhibition of the El 
reaction.150’ 151’ 152 However, binding of acetyl-CoA to this site occurs in the 
presence or absence of NADH and can therefore be accounted for by measuring 
acetyl-CoA incorporation in the absence of NADH. As can be seen in Table 21, 
S-acetyl-3-mercaptopropanoyl-CoA does inhibit incorporation of the acetyl 
group from the acetyl-CoA into the enzyme, and the degree of inhibition
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increases w ith increasing inhibitor concentration. That the inhibition requires 
a greater concentration of inhibitor than in the pyruvate dehydrogenase com­
plex assay can be explained by the greater concentration of enzyme protein 
used. These results lend support to the hypothesis tha t the enzyme is reacting 
w ith the inhibitor. In fact, in an experiment where BSA was included in the 
reaction in an amount ten times that of pyruvate dehydrogenase complex, inhi­
bition was significantly reduced, but still occurred and increased w ith increas­
ing S-acetyl-3-mercaptopropanoyl-CoA concentration.
The data strongly suggest that S-acetyl-3-mercaptopropanoyl-CoA inhi­
bits the pyruvate dehydrogenase complex by donating the S-acetyl-3- 
mercaptopropanoyl group to the dihydrolipoate moiety of the enzyme to form 
S-acetyl-3-mercaptopropanoyl lipoate, thereby making the lipoate unavailable 
to accept an acetyl group in the normal reaction. This would be similar to the 
irreversible inhibition of the E. coli pyruvate dehydrogenase complex by 2- 
bromopyruvate. This inhibition is due to the reductive bromoacetylation of 
lipoyl moieties of the E2 subunit.153’ 154 It is suggested, in addition, that S- 
acetyl-3-mercaptopropanoyl-CoA is formed intram itochondrially under certain 
conditions and, once formed, inhibits pyruvate-supported respiration by direct 
inhibition of the pyruvate dehydrogenase complex.
Some preliminary work has been done to examine the possibility th a t S- 
acetyl-3-mercaptopropanoyl-CoA formed intram itochondrially affects 
pyruvate-supported respiration. Since 3-mercaptopropanoic acid is known to 
be activated in rat heart mitochondria98 and to inhibit palm itoy W-carnitine- 
supported respiration97 , its effect was compared to th a t of S-acetyl-3- 
mercaptopropanoic acid. As can be seen in Table 22, S-acetyl-3-
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mercaptopropanoic acid was comparable to 3-mercaptopropanoic acid in its 
ability to inhibit both palmitoyl-Z-carnitine- and pyruvate-supported respira­
tion in both ra t heart and ra t liver mitochondria. One unusual aspect of these 
data is th a t pyruvate-supported respiration was inhibited significantly in rat 
liver mitochondria, but not in ra t heart mitochondria. This is consistent w ith 
the observation that propanoate (known to be activated to propanoyl-CoA 
which inhibits pyruvate dehydrogenase) inhibits flux through the pyruvate 
dehydrogenase in perfused rat liver, but not ra t heart.155 This may have to do 
w ith the difference in the activation enzymes of these tissues and thus the 
difference in intramitochondrial concentration of the CoA derivative maintained 
in each of these tissues.
The data in this table indicate that S-acetyl-3-mercaptopropanoyl-CoA is 
formed intramitochondrially and is as potent an inhibitor as the metabolites of 
3-mercaptopropanoic acid. The fact tha t S-acetyl-3-mercaptopropanoic acid 
was also a potent inhibitor of palmitoyl-Z-carnitine-supported respiration and 
that the pattern of inhibition so closely paralleled tha t of 3-mercaptopropanoic 
acid led to the suspicion tha t perhaps the acetyl group is cleaved from the S- 
acetyl-3-mercaptopropanoic acid to form 3-mercaptopropanoic acid and/or its 
derivatives. If this were the case, the data would be the same because inhibi­
tion would be due to 3-mercaptopropanoic acid metabolites. To avoid this 
confusion, work was pursued in a manner that was considered to result in the 
formation of S-acetyl-3-mercaptopropanoic acid intramitochondrially w ithout 
the introduction of S-acetyl-3-mercaptopropanoic acid. One way in which this 
could be accomplished in rat heart mitochondria was to supply acetoacetate as 
substrate so that acetoacetyl-CoA would be formed intramitochondrially. In 
the presence of 3-mercaptopropanoyl-CoA, thiolase would utilize both
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substrates to form, as product, S-acetyl-3-mercaptopropanoyl-CoA.98
The data from using this strategy are presented in Table 23. As can be 
seen in this table, pyruvate-supported respiration in ra t heart mitochondria is 
not inhibited by 3-mercaptopropanoic acid when malate is used as primer. 
Pyruvate-supported respiration is inhibited, however, when acetoacetate (20 
jj. M) is being metabolized. This would indicate tha t S-acetyl-3- 
mercaptopropanoyl-CoA is formed intramitochondrially and inhibits 
pyruvate-supported respiration. However, pyruvate-supported respiration is 
inhibited to the same extent in the absence of acetoacetate, when a-  
ketoglutarate is used as primer. This may mean that a-ketoglutarate somehow 
provides the acetyl group involved in the acetylation of 3-mercaptopropanoyl- 
CoA.
As stated previously, both 3-mercaptopropanoyl-CoA and S-acetyl-3- 
mercaptopropanoyl-CoA inhibit the pyruvate dehydrogenase complex. Under 
optimal conditions, 50% inhibition was obtained at 12.6 £iM 3- 
mercaptopropanoyl-CoA or 5.2 *uM S-Acetyl-3-mercaptopropanoyl-CoA. In 
addition, inhibition by S-acetyl-3-mercaptopropanoyl-CoA was greater than 
50% complete in 5 seconds. W hile tha t caused by 3-mercaptopropanoyl-CoA 
was 50% complete in approximately 1 min. Both inhibitors appear to be more 
potent under conditions where the endogenous lipoate moiety of the enzyme is 
reduced.
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Table 1. Effects o f  M etabolites and Coenzym es on the Fatty Acyl-CoA
Synthetase o f  Rat Heart M itochondria
Effectors 
(nm ol/m in/m g protein)
Specific Activity 
(%)
Relative Activity
None 11 ± 1 100
1 mM octanoylcamitine 11 ± 3 104
5 mM acetoacetate 10 ± 1 96
10 mM DL-3-hy droxy buty  rate 10 ± 1 93
None 10 ± 4 100
10 mM pyruvate 11 ± 1 115
1 mM NAD+ 11 ± 1 109
1 mM NADH 11 ± 2 116
None 7 ± 2 100
10 mM Lactate 7.8 ±0.1 114.5
0.1 mM fructose-1,6-diphosphate 7 ± 1 107
5 mM ADP 4.0 ± 0.2 58.7
Values are means ±S.E. The values are based on three assays w ith one 
preparation of mitochondria. Each grouping used a different mitochondrial 
preparation. The concentration of each effector was selected such th a t it was 
likely to be equal to or greater than its concentration in ra t heart cytosol. This 
was estimated from the literature values of the acylcarnitine8, acetoacetate , 
/3-hydroxy buty rate , pyruvate , NAD+C, NADH , lactate , fructose-1,6- 
diphosphate , and ADP content of heart tissue in /imole/g fresh w t. and the 
value of 2 m l/g dry tissue6 for the cytosolic space in heart muscle. Additional 
details of the experiment are described under "Experimental Procedures".
a M. M. Abdel-Kader, and G. W olf in Recent Research on Carnitine, ed. G. W olf, p. 147, M.l.T. 
Press, Cambridge, Mass., 1965.
^ O. Kraupp, L. Adler-Kastner, H. Niessner, and B. Plank, Eur. J. Biochem., vol. 2, p. 197, 1967.
c H. B. Burch, O. H. Lowry, and P. von Dippe, J. Biol. Chem., vol. 238, p. 2838, 1963.
** P. Arese, A. Bosia, and G. Pescarmona, unpublished results, in Methods in Enzymatic Analysis, 
ed. H. U. Bergmeyer, and K. Gawehn, vol. 4 , p. 2295, Academic Press, Inc., N.Y., 1974.
e H. E. Morgan, D. M. Regen, and C. R. Park, J. Biol. Chem., vol. 239, pp. 369-374, 1964.
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Table 2. Effect o f P a lm ito y lca rn itin e  on R at H eart M itochondria  F a tty  
Acyl-CoA Synthetase
Concentration
(mM)
Specific Activity 
(nm ol/m in/m g protein)
% Inhibition
0 13 ± 1 0
0.020 11 ± 3 17
0.20 10 ± 1 25
1.00 7 ± 1 45
0 12 ± 1 0
0.2 10 ± 1 17
0.5 9 ± 2 24
2.0 7 ± 1 37
Values are means ±S.E. The values are based on three assays w ith one 
preparation of mitochondria. Each grouping of data used a different mitochon­
drial preparation. Additional details of the experiment are described under 
" Experimental Procedures".
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Table 3. S eparation  o f O uter M itochondria l M em brane and  In term em ­
b ran e  Fraction  From  Inner M em brane F raction  o f Beef H eart 
M itochondria  by  D igitonin  T rea tm en t
F atty  Acyl-CoA Synthetase
Specific Activity of Mitochondria 
Activity of "outer" fraction 
Total Activity of mitochondria used 
Total Activity Recovered in "outer" fraction
8.2 nmol/m in/m g protein 
28.4 nm ol/m in/m l 
791 nmol/min 
44 nmol/min
Carnitine Palmitoyltransferase 
Specific Activity of Mitochondria 
Specific Activity of "outei" fraction 
Total Activity in "outer" fraction
4.4 nmol/min/mg protein 
2.1 nmol/m in/m g protein 
20.2 nmol/min
Carnitine palm itoyltransferase activity was assayed by the spectrophotometric 
method. Details of the experiment are described under "Experimental Pro­
cedures" .
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Table 4. Effect o f R egulators o f P ro te in  Kinases o r Phosphatases on the  
A c tiv ity  o f  F a tty  Acyl-CoA S y n th e tase
Experiments were performed using heart tissue homogenate. Specific 
activity is expressed in nm ol/m in/m g protein. Values are means ± 
S. E. Figures in parentheses are the number of observation w ith 
samples from different animals. Each sample was assayed a 
minimum of tw o times. O ther details of the experiment are 
described under "Experimental Procedures".
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Effectors Included in 
Preincubation Mixture 
Only
Effectors Included in 
Preincubation Mixture 
and Assay Mixture
Specific
A ctivity
%
Stimulation
Specific
A ctivity
%
Stim ulation
Preincubation at 25°C for 20 min in:
100 mM Tris-HCl buffer, 
pH 7.4
15.4 ± 0 .5 (4 ) 0 15.4 ± 0.5(4) 0
Buffer, 5 mM Mg-ATP, 
0.25 mM CaCl2
16.8 ± 1.1(3) 9.1 17.5 ± 1.1(3) 13.7
Buffer, 5 mM Mg-ATP, 
calmodulin (1 /ig/m g protein)
18.5 ± 1.1(3) 20.5 18.9 ± 1.0(3) 23.1
Buffer, 5 mM Mg-ATP,
0.25 mM CaCl2, 
calmodulin (1 MS/mg protein)
19.0 ± 0 .5 (3 ) 23.5 17.6 ± 0 .7 (3 ) 14.4
Buffer 12.6 ± 0 .4 (5 ) 0 12.8 ± 0.4(5) 0
Buffer, 5 mM Mg-ATP, 
25 fxM CaCl2
12.5 ± 2 .0 (4 ) 0 12.3 ± 1.1(4) 0
Buffer, 5 mM Mg-ATP, 
1 mM EGTA
13.1 ± 0 .5 (3 ) 2.9 13.2 ± 0 .6(3) 3.7
Buffer, 5 mM Mg-ATP, 
25 /uM CaCl.,
1 mM EGTA
13.8 ± 0 .4 (5 ) 8.5 13.0 ± 1.6(5) 2.0
Preincubation at 25°C for 30 min in:
Buffer 13.1 ± 1 .0 (4 ) 0 13.2 ± 1.0(4) 0
Buffer, 0.1 mM cAMP, 
5 mM MgCl2
13.4 ± 1.0(4) 2.8 12.7 ± 0 .6(4) 0
Buffer, 0.1 mM cAMP, 
5 mM Mg-ATP
13.6 ± 1.9(4) 4.0 14.7 ± 1.0(4) 12.3
Buffer, 0.1 mM cAMP, 5 mM 
Mg-ATP added after 15 min
14.0 ± 0 .2 (3 ) 7.5 13.8 ± 0.2(3) 5.7
Preincubation at 25°C for 20 min in:
Buffer 13.0 ± 1.8(5) 0 13.0 ± 1.8(5) 0
Buffer, 5 mM ATP/MgCl2 12.2 ± 1.4(5) 6.1 12.2 ± 1.4(5) 6.1
Buffer, 5 mM ATP/MgCl , 
50 mM KF
12.1 ± 1.1(5) 7.1 12.1 ± 1.0(3) 6.8
Buffer, 50  mM KF 12.7 ± 0 .6 (5 ) 2.7 12.7 ± 0.3(3) 2.7
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Table 5. Effecs o f  M etabolites and Coenzym es on C arnitine P alm itoy l­
transferase from  R at Heart M itochondria
Carnitine palm itoyltransferase activity was assayed by the radiochemical 
method. Values are means ±S.E. Figures in parentheses are the number of 
observations w ith samples from different animals. Each sample was assayed a 
minimum of tw o times. The concentration of each effector was selected such 
th a t it was likely to be equal to  or greater than its concentration in ra t heart 
cytosol. This was estimated from the literature values of the /3- 
hydroxy buty rate0, ATP°, ADP , acetylcarnitinec, fructose-1,6-diphosphate°, 
NAD+ , NADH , pyruvate0, lactate0, and acylcamitine6 content of heart tissue 
in Atmole/g fresh w t. and the value of 2 m l/g d ry  tissue for the cytosolic space 
in heart muscle. Other details of the experiment are described under "Experi­
m ental Procedures".
0 O. Kraup, L. Adler-Kastner, H. Niessner, and B. Plank, Ear. J. Biochem., vol. 2, p. 197, 1967.
P. A iese, A. Bosia, and G. Pescarmona, unpublished results, in  Methods o f Enzymatic Analysis, 
ed. H. U. Bergmeyer, and K. Gawehn, vol. 4, p. 2295, Academic Press, Inc., N. Y., 1974.
c D. J. Pearson, and P. K. Tubbs, Biochem. J., vol. 105, p. 953, 1967.
d H. B. Burch, O. H. Lowry, and P. von  Dippe, J. Biol. Chem., vol. 238, p. 2838, 1963.
e M. M. Abdel-Kader, and G. W olf, in Recent Research on Carnitine, ed. G. W olf, p. 147, M.I.T. 
Press, Cambridge, Mass,, 1965.
 ^ H. E. Morgan, D. M. Regen, and C. R. Park, J. Biol. Chem., vol. 239, pp. 369-374, 1964.
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Table 5. Effects o f  M etabolites and Coenzym es on C arnitine P a lm itoy l­
transferase from  Rat Heart M itochondria
Effectors Specific Activity 
(nm ol/m in/m g protein)
% Inhibition
None 14 (1)
10 mM /3-hydroxy buty  rate 13 (1) 12
None 12 ± 1 (2 )
5 mM ATP 10 ± 0 (2 ) 18 ± 1
5 mM ADP 8 ± 1(2) 32 ± 5
None 11 ± 0 (3 )
1 mM acety 1-Z-carnitine 11 ± 3 (2 ) 6 ±28
0.1 mM fructose-1,6-diphosphate 10 ± 1 (3 ) 15 ±10
1 mM NAD+ 12 ± 2 (3 )
1 mM NADH 12 ± 1 (3 )
None 16 ± 5 (4 )
10 mM pyruvate 18 ± 1(4)
10 mM lactate 17 ± 4 (4 )
1 mM octanoy W-carnitine 15 ± 2 (3 ) 6 ±12
10 mM /3-hydroxybutyrate 15 ± 1(4) 8 ± 8
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Table 6. Effects o f  M etabolites on C arnitine P alm itoyltransferase A  o f
Rat Heart M itochondria
Effectors Specific Activity 
(nmol/min/mg protein)
% Inhibition
None
100 yuM malonyl-CoA 
100 f iM  methylmalonyl-CoA 
100 £im acetyl-CoA
12.5 (1) 
5.1 (1)
10.1 (1)
13.6 (1)
59.4
18.6
None 7.7 (1)
100 /xM malonyl-CoA 3.1 (1) 59.8
100 /xM methylmalonyl-CoA 7.0 (1) 9.6
100 ^iM acetyl-CoA 9.7 (1)
100 xxM acetoacetyl-CoA 8.4 (1)
None 9.0 (1)
100 /uM malonyl-CoA 3.6 (1) 59.7
100 mM succinyl-CoA 4.0 (1) 55.4
None 13.4 (1)
100 jjlM  succinyl-CoA 7.0 (1) 52.2
100 fjLM acetoacetyl-CoA 13.7 (1)
100 /uM acetyl-CoA 13.4 (1)
100 ftM methylmalonyl-CoA 11.2 (1) 16.6
10 mM pyruvate 16.9 (1)
10 mM lactate 17.2 (1)
None 16.1 (1)
100 ytxM malonyl-CoA 2.1 (1) 86.9
100 piM malonyl-CoA + Triton X-100 13.4 (1) 16.3
0.09% Triton X-100 12.6 (1) 21.4
None
100 juM malonyl-CoA 
100 /xM succinyl-CoA 
100 fjiM acetoacetyl-CoA 
100 /xM acetyl-CoA 
100 juM methylmalonyl-CoA
11.4 ±1.0(3) 
0.7 ±0.0(3) 
3.5 ±0.8(3)
8.0 ±1.1(3) 
9.3 ±1.1(3)
6.0 ±0.8(3)
93.6
69.0 
29.8 
18.3
47.0
CPT A activity was assayed using the radiochemical method. Values are 
means ± S. E. Figures in parentheses are the number of observations w ith 
samples from different animals. Each sample was assayed a minimum of tw o 
times. Other details of the experiment are described in "Experimental Pro­
cedures" .
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Table 7. Loss o f CoASH D erivatives D uring T im e and  C onditions of the  
Assay fo r  C arn itin e  P a lm ito y ltran sferase  A A ctiv ity
Derivative 
(100 wM)
Specific Activity 
nm ol/m in/0.05 me protein
w ithout carnitine w ith carnitine
succinyl-CoA 0.44 1.25
malonyl-CoA 0 0.19
acetyl-CoA 0 0.15
acetoacetyl-CoA 0.15 0
methylmalonyl-CoA 0 0
Values are based on tw o assays w ith one preparation of mitochondria. Other 
details of the experiment are described under "Experimental Procedures".
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Table 8. R elationsh ip  Between C oncen tration  o f M alonyl-CoA or 
Succinyl-CoA and  Degree o f In h ib itio n  o f C arn itin e  P alm itoy l­
tra n sfe ra se  A
Inhibitor Concentration
U M )
Specific Activity 
(nm ol/m in/m g protein)
% of Control 
Activity
None 10.4 ±  2.2 100
Malonyl-CoA 100 3.3 ±0.1 31
10 4.6 ± 0 .9 44
1 6.1 ±0.1 59
0.1 7.8 ± 2 .8 76
0.01 10.8 ±2 .8 103
Sucdnyl-CoA 100 4.7 ±  1.2 45
10 7.6 ±0.1 72
1 10.8 ± 0 .0 104
0.1 11.1 ±0.7 107
0.01 10.4 ± 1.5 99
Carnitine palmitoyltransferase A activity was assayed by the radiochemical 
method. Values are means ± S. E. Values are based on assays w ith two 
different preparations of mitochondria. Other details of the experiment are 
described under "Experimental Procedures".
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Table 9. In h ib itio n  o f R at H eart M itochondrial C arn itin e  P alm itoy l­
tra n sfe ra se  A by  M alonyl-CoA and S tru c tu ra lly  Related Com­
pounds
Inhibitor 
(100 /iM )
Inhibition
(%)
malonyl-CoA
succinyl-CoA
acetyl-CoA
acetoacetyl-CoA
methylmalonyl-CoA
70 ± 1 5  
59 ± 0 
-4 ± 2 0  
6 ± 27  
23 ± 1 6
Carnitine palmitoyltransferase A activity was assayed by the radiochemical 
method. Values are based on the experimental results presented in Table 6. 
Other details of the experiment are described under " Experimental Procedures".
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Table 10. Enzym e A ctiv ities  o f Subcellu lar Fractions O btained by 
M ethod I
Time
(m in)
Specific
A ctivity
(M m ol/min/mg)
Total
A ctivity
(#tm ol/m in)
% of 
Combined
A ctivity
Succinate Thiokinase
'whole heart homogenate 0 0
5 6.8 46.1 100
20 3.4
40 1.3
cytoplasm 0 0
5 2.0 12.8 27.8
20 0.9
40 0.7
extracytoplasmic fraction 0 0
5 27.3 39.0 84.4
20 8.5
Enoyl-CoA Hydratase
cytoplasm 1.0 ± 0 .2 6.5 9.8
extracytoplasmic fraction 41 ± 9 59 90
3-H ydroxyacyl-CoA Dehydrogenase
cytoplasm 0.2 ± 0 .0 1.0 29.9
extracytoplasmic fraction 2 ± 1 2 70
Citrate Synthase
cytoplasm 0.3 ± 0 .0 1.9 18.3
extraclytoplasmic fraction 6.1 ± 1 .1 8.6 81.7
Values are mean ± S. E. The values for succinate thiokinase are based on one 
assay. The values for the other enzymes are based on three assays. All assays 
were performed on the same preparation of subcellular fractions. Other details 
of the experiment are included in " Experimental Procedures".
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Table 11. Enzym e A ctiv ities  o f Subcellu lar Fractions O btained by 
M ethod II
Specific Activity  
(Atntol/min/mg)
Total Activity  
(/umol/min)
% of Combined 
A ctivity
Succinate Thiokinase
cytosol 2.7 x 10'3 50.8 x 10'3 41.5
mitochondria 76.4 x 10'3 71.7 x 10'3 58.5
Enoyl-CoA Hydratase
cytosol 1.0 ± 0 .1 19.6 33.3
mitochondria 41 ± 4 39 67
3-H ydroxyacyl-CoA Dehydrogenase
cytosol 0.2 ± 0 .0 3.0 44.5
mitochondria 4.0 ± 0 .2 3.8 55.5
Citrate Synthase
cytosol 0.3 ± 0 .0 5.7 40.9
mitochondria 8.8 ± 0 .6 8.2 59.1
Values are mean ± S. E. The values for succinate thiokinase are based on tw o 
assays. The values for the other enzymes are based on three assays. A ll 
assays were performed on the same preparation of subcellular fractions. Other 
details of the experiment are described under "Experimental Procedures".
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Table 12. Rates o f R espiration Supported by  F a tty  Acid O xidation in  Rat 
L iv er and R at H eart M itochondria
(Data is expressed in nanoatoms 0 2 consumed/min/mg protein)
Substrate Rat Heart Rat Liver
Palmitoyl-CoA
Oleoyl-CoA
Lineoyl-CoA
167.1 ±18 .8
174.0 ±26.1
154.1 ±23 .9
73.7 ± 9 .7
78.7 ± 8 .9  
73.9 ±  8.4
RCR 4.3 ±  0.6 4.9 ± 0 .9
Values are means ± S. E. The values are based on three assays each w ith three 
different preparations of mitochondria. Other details of the experiment can be 
found under "Experimental Procedures".
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Table 13. Substrate U tiliza tion  by  R at H eart M itochondria
Substrate Specific Activity 
(nmol consumed/min/mg protein)
Palmitoyl-CoA 3.6 ±0 .4
Oleoyl-CoA 3.4 ±0 .5
Linoleoyl-CoA 3.1 ±0 .5
Values are means ± S. E. The values are based on three assays each w ith three 
different preparations of mitochondria. Other details of the experiment can be 
found u n d er" Experimental Procedures".
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Table 14. A ctiv itie s  o f  A u x iliary  Enzym es o f  /3-Oxidation Required fo r
th e D egradation o f Polyunsaturated F atty  Acids in  Rat L iver
and Rat H eart M itochondria
Enzyme Rat Heart Rat Liver
3-Hydroxyacyl-CoA epimerase 
C-12 substrate 
C-8 substrate
3.4 ± 0.5(3) 
2.0 ± 0.3(3)
84.9 ± 8.4(7) 
79.3 ± 14.4(5)
cis-A^-trans-A^-enoyl-CoA isomerase 745 ±93 (3) 721 ±134 (3)
2,4-Dienoyl-CoA reductase 27.4 ±  5.1(3) 73.6 ±  17.0(5)
Data is expressed in nm ol/m in/m g protein. Values are means ±  S. E. Figures 
in parentheses are the number of observations w ith samples from different 
animals. Each sample was assayed a minimum of three times.
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Table 15. Recovery of P y ru v a te  Dehydrogenase Complex by  Rapid Gel 
F iltra tio n
% volume 
recovered
% activity 
recovered
% of control activity 
prefiltration post-filtration
Control 85 ± 4 46 ± 7 100 100
Inhibited 88 ± 8 49 ± 16 11.2 ± 2 12 ± 3
% S-acetyl-3-mercaptopropanoyl-CoA remaining in eluate -  8.4 % 
Concentration of S-acetyl-3-mercaptopropanoyl-CoA in eluate = 19.8 f iM 
Concentration of S-acetyl-3-mercaptopropanoylCoA in assay = 0.8 /aM
Details of the experiment can be found under "Experimental Procedures".
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Table 16. In h ib itio n  o f P y ru v a te  D ehydrogenase Complex b y  E nzym ati­
ca lly  Synthesized S-Acetyl-3-M ercaptopropanoyl-CoA  as Com­
pared  to  C hem ically  Synthesized S-Acetyl-3-M ercapto- 
propanoyl-CoA  and  3-M ercaptopropanoyl-CoA
Pyruvate Dehydrogenase Complex A ctivity (% of control)
Concentration S-Acetyl-3-M ercaptopropanoyl-CoA 3-Mercaptopropanoyl-CoA
o f Inhibitor Enzym atically Chemically
(«M ) Synthesized Synthesized
26.7 35 ± 2 35 ± 1 47 ± 5
13.6 49 ± 10 56 ± 7 62  ± 5
6.8 68 ± 1 87 86 ± 18
The S-Acetyl-3-Mercaptopropanoyl-CoA w as enzymatically synthesized via 
the thiolase reaction as described under " Experimental Procedures". The con­
tro l reaction included CoASH instead of 3-mercaptopropanoyl-CoA in the 
thiolase reaction. Chemically synthesized 3-mercaptopropanoy 1 -CoA and S- 
acetyl-3-mercaptopropanoyl-CoA were added to the assay mixture just prior to 
the preincubation period. The enzyme was preincubated for 3 min a t 30°C in 
the presence of KPi, MgCL, TPP, CoASH, and pyruvate. The reaction was ini­
tiated by the addition of NAD+. Other details of the experiment are described 
under "Experimental Procedures".
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Table 17. Inhibition of Pyruvate Dehydrogenase Complex by 3- 
Mercaptopropanoyl-CoA as a Function of Different Preincuba­
tion Conditions
Preincubation
Components
Initiation
Components
Initial
(pm ol/m ir
Control
Velocity 
i/m g protein) 
Inhibited
% of 
Control
TPP, CoASH, pyruvate NAD4 1.5 ± 0.3 0.3 ± 0.1 6.5
TPP, CoASH NAD4, pyruvate 2.7 ± 0 .3 0.6 ± 0.1 21.1
TPP, NADH NAD4, pyruvate, CoASH 1.6 ±  0.2 0.2 ± 0.1 5.8
TPP, pyruvate, NAD+ CoASH 2.0 ± 0.2 1.1 ± 0 .2 54.4
TPP, CoASH, NAD+ pyruvate 2.1 ± 0 .2 1.2 ± 0 .6 72.5
TPP NAD4, pyruvate, CoASH 1.9 ± 0 .3 0.5 ± 0.2 28.3
TPP, pyruvate NAD4, CoASH 1.8 ± 0 .5 0.3 ± 0.1 17.1
TPP, NAD+ pyruvate, CoASH 2.2 ± 0 .1 1.7 ± 0 .1 79.1
CoASH, pyruvate TPP, NAD4 2.2 ± 0.5 0.4 ± 0 .1 19.5
The enzyme was preincubated for 3 min a t 30°C in the presence of KPi, MgCl2> 
and various components of the assay mixture. The reaction was initiated by 
the addition of those assay components not present during the preincubation. 
The 3-mercaptopropanoyl-CoA, when included in the preincubation mixture, 
was a t a concentration of 30.5 ytiM. Other details of the experiment can be 
found under "Experimental Procedures".
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Table 18. Inhibition of Pyruvate Dehydrogenase Complex by S-Acetyl-3- 
Mercaptopropanoyl-CoA as a Function of Different Preincuba­
tion Conditions
Preincubation
Components
Initiation
Components
Initial
(jumol/mir
Control
Velocity  
i/m g protein) 
Inhibited
% of
Control
TPP, CoASH, pyruvate NAD+ 2.7 ± 0.3 0.2 ± 0.1 8.2
TPP, CoASH NAD+, pyruvate 5.1 ± 0 .4 0.5 ± 0 .1 9.4
TPP, pyruvate, NAD+ CoASH 2.5 ± 0.4 1.3 ± 0.0 51.2
TPP, CoASH, NAD+ pyruvate 3.3 ± 0.3 1.8 ± 0.6 53.7
TPP NAD+, pyruvate, CoASH 3.3 ± 0.2 0.6 ± 0.1 16.8
TPP, pyruvate NAD+, CoASH 3.7 ± 0.3 1.2 ± 0.5 33.3
TPP, NAD+ pyruvate, CoASH 4.7 ± 0.8 2.8 ± 0 .7 58.8
CoASH, pyruvate TPP, NAD+ 5 .0  ± 0.6 0.6 ± 0.1 12.7
The enzyme was preincubated for 3 min a t 30°C in the presence of KPi, MgCl2, 
and various components of the assay mixture. The reaction was initiated by 
the addition of those assay components not present during the preincubation. 
The S-acetyl-3-mercaptopropanoyl-CoA, when included in the preincubation 
mixture, was at a concentration of 67.5 /uM. Other details of the experiment 
can be found under "Experimental Procedures".
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Table 19. Inhibition of Pyruvate Dehydrogenase - Lipoate Acetyl- 
transferase
The enzyme was preincubated for 3 min at room temperature in the presence of 
TRIS-HC1, MgCL, TPP, and CoASH. Either pyruvate, lipoamide or neither 
were included in The preincubation mixture. The reaction was initiated by the 
addition of either pyruvate, lipoamide or both as indicated. Acetyl-CoA pro­
duced was measured via the citrate synthase reaction. Other experimental 
details can be found under "Experimental Procedures".
I = S-Acetyl-3-Mercaptopropanoyl-CoA (67.5 fiM)
Preincubation Initiating Specific Activity Relative Activity
Conditions Component (A mol/min/mg) (%)
lipoamide pyruvate 1.2 ±0.2 100
lipoamide, I pyruvate 0.8 ±0.2 72
pyruvate lipoamide 1.1 ±0.2 100
pyruvate, I lipoamide 0.4 ±0.1 39
pyruvate, lipoamide 1.0 ±0.2 100
I pyruvate, lipoamide 0.7 ±0.2 68
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Table 20. Inhibition of Dihydrolipoyl Dehydrogenase
The enzyme protein was preincubated for 3 minutes at 30°C in the presence of 
KP. and one substrate. The reaction was initiated by the addition of the 
second substrate. A3. q was measured spectrophotometrically. Other experi­
mental details can be found under "Experimental Procedures".
I = S-Acetyl-3-Mercaptopropanoyl-CoA (67.5 /kM)
Dihydrolipoamide + NAD+ ..^ Lipoamide + NADH + H+
Preincubation Initiating Specific Activity Relative
Conditions Component (yumol/min/mg) Activity
Dihydrolipoamide NAD+ 6.8 ± 1.1 100
Dihydrolipoamide, I NAD+ 3.3 ± 0 .8 47.0 ± 5.3
NAD+ Dihydrolipoamide 5.6 ±0.1 100
NAD+. I Dih vdrolipoam ide 4.9 ± 0.3 88.1 ± 6.0
Lipoamide NADH 5.7 ± 0.8 100
Lipoamide, I NADH 5.4 ± 1.3 94.4 ± 18.3
NADH Lipoamide 5.8 ±0.2 100
NADH. I Lipoamide 3.1 ±0.2 53.0 ± 3.8
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Table 21. Inhibition of [ l-14C]-Acetyl Group Incorporation into the Pyru­
vate Dehydrogenase Complex
Experiment I
Inhibitor Concentration 
(mM)
Acetyl Bound/PDH Complex 
mol/mol
Acetyl Bound 
% of Control
0 50.7 100
47.8 31.0 61.1
980.7 4.3 8.5
Experiment II
Inhibitor Concentration 
UM )
Acetyl Bound/PDH Complex 
mol/mol
Acetyl Bound 
% of Control
0 34.5 100
47.8 21.9 63.6
119.6 17.8 51.7
239.2 7.1 20.7
478.4 1.5 5.2
Experiment I utilized porcine pyruvate dehydrogenase complex. Experiment II 
utilized the bovine enzyme. The enzyme (0.2-0.22 mg protein) was preincu­
bated at room temperature for 3 min. The preincubation mixture contained 
KPi, MgCl., TPP, NADH, and ± S-acetyl-3-mercaptopropanoyl-CoA (the inhi­
bitor). Tne reaction was initiated with [ l-  C]-acetyl-CoA. Other details of 
the experiment are described in " Experimental Procedures".
- 8 6 -
Table 22. Inhibition of Palmitoylcartine- and Pyruvate-Supported 
Respiration by 3-Mercaptopropanoic Acid and S-Acetyl-3- 
Mercaptopropanoic Acid
The mitochondria were preincubated 1 min in the presence of malate at which 
time the inhibitor (~ 800 /xM) was added. ADP was added to the chamber 3 
min after malate. The substrate was added to the chamber 4 min after malate. 
Values are means ± S. E. The values are based on at least two assays for each 
preparation of mitochondria. Figures in parentheses indicate the number of 
mitochondrial preparations studied. All preparations of mitochondria had 
RCR values larger than 4, using palmitoylcamitine as substrate. Other details 
of the experiment are described under "Experimental Procedures".
Rat Liver Mitochondria
Palmitoylcarnitine-Supported Respiration
Inhibitor Respiration Rate 
(% of Control)
3-mercaptopropanoic acid 
S-acetyl-3-mercaptopropanoic acid
40 ±11(4) 
32 ± 14(2)
Pyruvate-Supported Respiration
Inhibitor Respiration Rate 
(% of Control)
3-mercaptopropanoic acid 
S-acetyl-3-mercaptopropanoic acid
57 ± 8(4) 
56 ±20(2)
Rat Heart Mitochondria
Palmitoylcarnitine-Supported Respiration
Inhibitor Respiration Rate 
(% of Control)
3-mercaptopropanoic acid 
S-acetyl-3-mercaptopropanoic acid
17 ±15(3) 
27 (1)
Pyruvate-Supported Respiration
Inhibitor Respiration Rate 
(% of Control)
3-mercaptopropanoic acid 
S-acetyl-3-mercaptopropanoic acid
104 ± 0(2) 
99 (1)
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Table 23. Inhibition of Pyruvate-Supported Respiration in Rat Heart 
Mitochondria by 3-Mercaptopropanoic Acid in the Presence of 
Acetoacetate
The mitochondria were preincubated with primer. 3-Mercaptopropanoic acid 
(final concentration was 840.7 /zM) was added to the chamber 30 sec after the 
addition of primer. Acetoacetate was added to the chamber 1 min after the 
addition of primer. Substrate was added to the chamber 4.5 min after the 
addition of primer. Values are means ± S. E. The values are based on at least 
two assays for each preparation of mitochondria. Figures in parentheses indi­
cate the number of mitochondrial preparations studied. All preparations of 
mitochondria had RCR values larger than 4, using palmitoylcarnitine as sub­
strate. Other details of the experiment are described under "Experimental Pro­
cedures" .
Conditions Rate of Respiration 
(natom O /m in/m g)
% of 
Control
Primer Other
Additions
Substrate Control Inhibited
malate palm itoyl­
carnitine
105.6 ± 10.7(2) 7.4 ±  3 .2(2) 6.6
malate pyruvate 274.2 (1) 202.3  (1 ) 81.8
a-KGa 67.4 ± 0.0(2) 67.4  ± 0 .0 (1 ) 100.0
a-KG acetoacetate 80.9 ± 0.0(2) 103.4 ± 0 .0 (2 ) 127.8
a-KG acetoacetate pyruvate 238.2 ± 0.0(2) 105.6 ± 3 .2 (2 ) 44.3
a-KG pyruvate 209.0  ± 3.2(2) 96.7 ± 3 .2(1) 46.2
a a-K G  = a-ketoglutarate
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Figure 1. Schematic Representation of Fatty Acid Activation and Tran­
sport Across the Mitochondrial Membranes
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Figure 2. Pathw ay  o f  Linoleic Acid Degradation
A, pathway proposed by Stoffel and Caesar85. B, modified pathway supported 
by findings published by Kunau and Dommes , as well as Cuebas and 
Schulz . Reactions catalyzed by: (1) acyl-CoA dehydrogenase; (2) enoyl-CoA 
hydratase; (3) L-3-hydroxyacyl-CoA dehydrogenase; (4) 3-ketoacyl-CoA 
thiolase; (5) 3-hydroxyacyl-CoA epimerase; (6) cis-A-trans-A -enoyl-CoA 
isomerase; (7) 2,4-dienoyl-CoA reductase.
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Figure 3. Mitochondrial Metabolism of 3-Mercaptopropanoic Acid
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Figure 4. Effect of Palm itoylcaraitine on A ctivity of Palmitoyl-CoA Syn­
thetase in Rat Heart Mitochondria
The figure was generated from the experimental data in Table 2. 
The curve is a theoretical curve based on linear regression analysis. 
Other details of the experiment can be found under "Experimental 
Procedures".
100
90 >.
80
o>
70 .E
60
50
0 I 2
Palmitoyl carnitine (mM)
Re
m
ai
ni
ng
 
Ac
tiv
ity
 
(%
)
- 92  -
Figure 5. Concentration Dependence of Inhibition by Malonyl-CoA and 
Succinyl-CoA of Carnitine Palmitoyltransferase A 
CPT A activity was assayed by the radiochemical method. The 
filled circles indicate malonyl-CoA. The opened circles indicate 
succinyl-CoA. The figure was generated from the data in Table 8. 
Other details of the experiment can be found under "Experimental 
Procedures".
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Figure 6. Inhibition of Pyruvate Dehydrogenase Complex by 3- 
Mercaptopropanoyl-CoA and S-Acetyl-3-Mercaptopropanoyl- 
CoA
A, As a Function of Concentration
B, As a Function of Time
A, The enzyme was preincubated for 3 min at 30°C in the presence
of KPf, MgCl2, TPP, CoASH, pyruvate, and the inhibitor. The reac­
tion was initiated with NAD+.
B, The enzyme was preincubated for 3 min at 30°C in the presence of 
KPf, MgCL, TPP, CoASH, and pyruvate. The inhibitor was added 
to provide Tor preincubation for the lengths of time indicated.
The solid line indicates S-acetyl-3-mercaptopropanoyl-CoA. The 
dashed line indicates 3-mercaptopropanoyl-CoA. Each value 
represents the mean of a minimum of three assays. The curves are 
theoretical curves generated by linear regresion analysis.
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Figure 7. Inhibition of Pyruvate Dehydrogenase by 3- 
Mercaptopropanoy 1-CoA as a Function of Different Preincuba­
tion Conditions
The enzyme was preincubated for 3 min at 30°C in the presence of 
KPi, MgCl2, and various components of the assay mixture. The 
reaction was initiated by the addition of those assay components not 
present during the preincubation. The dashed line indicates the 
presence of 30.5 fiM 3-mercaptopropanoyl-CoA in the preincubation 
mixture.
Symbol Preincubation 
Components
o
X
o
A
TPP, CoASH, Pyruvate 
TPP, NADH 
/  TPP, NAD+, CoASH 
L t p p , NAD+
TPP, Pyruvate 
C  TPP, CoASH
TPP, Pyruvate, NAD+ 
TPP
v. CoASH, Pyruvate
Initiating
Components
NAD+
CoASH, Pyruvate, NAD+ 
Pyruvate 
CoASH .Pyruvate 
NAD+, CoASH 
NAD+, Pyruvate 
CoASH
NAD+, Pyruvate, CoASH 
TPP, NAD+
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Figure 7.
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Figure 8. Inhibition of Pyruvate Dehydrogenase by S-Acetyl-3- 
Mercaptoprqpanoyl-CoA as a Function of Different Preincuba­
tion Conditions
The enzyme was preincubated for 3 min at 30°C in the presence of 
KPi, MgCl2, and various components of the assay mixture. The 
reaction was initiated by the addition of those assay components not 
present during the preincubation. The dashed line indicates the 
presence of 67.5 fxM S-acetyl-3-mercaptopropanoyl-CoA in the 
preincubation mixture.
mbol Preincubation Initiation
Components Components
• TPP, CoASH. Pyruvate NAD+
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I TPP, pyruvate NAD+, CoASH
LCoASH, Pyruvate TPP, NAD+
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Figure 9. Schem atic R epresen tation  o f th e  P y ru v a te  D ehydrogenase Com­
plex
El = Pyruvate Dehydrogenase 
E2 = Lipoate Acetyl Transferase 
E3 = Dihydrolipoyl Dehydrogenase
+
X+
LiL.
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